ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PCTL PCT Ltd (CE)

0.0001
0.00 (0.00%)
26 Nov 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
PCT Ltd (CE) USOTC:PCTL OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.0001 0.00 00:00:00

Quarterly Report (10-q)

15/11/2021 6:50pm

Edgar (US Regulatory)


0001119897 false True Q3 12/31 09/30/2021 NV Non-accelerated Filer True 27,380,040 5,563,299 P1Y P3Y10M28D P3M26D January 26, 2022 P2Y2M5D December 3, 2023 P2Y5M12D March 13, 2024 P3Y10M28D August 26, 2025 0001119897 2021-01-01 2021-09-30 0001119897 2021-11-15 0001119897 2021-09-30 0001119897 2020-12-31 0001119897 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001119897 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001119897 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001119897 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001119897 us-gaap:SeriesCPreferredStockMember 2021-09-30 0001119897 us-gaap:SeriesCPreferredStockMember 2020-12-31 0001119897 2021-07-01 2021-09-30 0001119897 2020-07-01 2020-09-30 0001119897 2020-01-01 2020-09-30 0001119897 us-gaap:CommonStockMember 2019-12-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001119897 us-gaap:RetainedEarningsMember 2019-12-31 0001119897 2019-12-31 0001119897 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001119897 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001119897 2020-01-01 2020-03-31 0001119897 us-gaap:CommonStockMember 2020-03-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001119897 us-gaap:RetainedEarningsMember 2020-03-31 0001119897 2020-03-31 0001119897 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001119897 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001119897 2020-04-01 2020-06-30 0001119897 us-gaap:CommonStockMember 2020-06-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001119897 us-gaap:RetainedEarningsMember 2020-06-30 0001119897 2020-06-30 0001119897 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001119897 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001119897 us-gaap:CommonStockMember 2020-09-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001119897 us-gaap:RetainedEarningsMember 2020-09-30 0001119897 2020-09-30 0001119897 us-gaap:CommonStockMember 2020-12-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001119897 us-gaap:RetainedEarningsMember 2020-12-31 0001119897 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001119897 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001119897 2021-01-01 2021-03-31 0001119897 us-gaap:CommonStockMember 2021-03-31 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001119897 us-gaap:RetainedEarningsMember 2021-03-31 0001119897 2021-03-31 0001119897 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001119897 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001119897 2021-04-01 2021-06-30 0001119897 us-gaap:CommonStockMember 2021-06-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001119897 us-gaap:RetainedEarningsMember 2021-06-30 0001119897 2021-06-30 0001119897 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001119897 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001119897 us-gaap:CommonStockMember 2021-09-30 0001119897 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001119897 us-gaap:RetainedEarningsMember 2021-09-30 0001119897 us-gaap:FairValueInputsLevel1Member 2021-09-30 0001119897 us-gaap:FairValueInputsLevel2Member 2021-09-30 0001119897 us-gaap:FairValueInputsLevel3Member 2021-09-30 0001119897 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001119897 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001119897 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001119897 2020-07-01 2021-06-30 0001119897 2020-11-01 2021-09-30 0001119897 2021-04-01 2021-09-30 0001119897 PCTL:NotesPayable1Member 2021-09-30 0001119897 PCTL:NotesPayable1Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable1Member 2020-12-31 0001119897 PCTL:NotesPayable2Member 2021-09-30 0001119897 PCTL:NotesPayable2Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable2Member 2020-12-31 0001119897 PCTL:NotesPayable3Member 2021-09-30 0001119897 PCTL:NotesPayable3Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable3Member 2020-12-31 0001119897 PCTL:NotesPayable4Member 2021-09-30 0001119897 PCTL:NotesPayable4Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable4Member 2020-12-31 0001119897 PCTL:NotesPayable5Member 2021-09-30 0001119897 PCTL:NotesPayable5Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable5Member 2020-12-31 0001119897 PCTL:NotesPayable6Member 2021-09-30 0001119897 PCTL:NotesPayable6Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable6Member 2020-12-31 0001119897 PCTL:NotesPayable7Member 2021-09-30 0001119897 PCTL:NotesPayable7Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable7Member 2020-12-31 0001119897 PCTL:NotesPayable8Member 2021-09-30 0001119897 PCTL:NotesPayable8Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable8Member 2020-12-31 0001119897 PCTL:NotesPayable9Member 2021-09-30 0001119897 PCTL:NotesPayable9Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable9Member 2020-12-31 0001119897 PCTL:NotesPayable10Member 2021-09-30 0001119897 PCTL:NotesPayable10Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable10Member 2020-12-31 0001119897 PCTL:NotesPayable11Member 2021-09-30 0001119897 PCTL:NotesPayable11Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayable11Member 2020-12-31 0001119897 PCTL:NotesPayableTotalMember 2021-09-30 0001119897 PCTL:NotesPayableTotalMember 2020-12-31 0001119897 PCTL:NotesPayable4Member 2020-10-01 2020-12-31 0001119897 2020-10-01 2020-12-31 0001119897 PCTL:NotesPayable5Member 2020-11-01 2020-12-31 0001119897 PCTL:NotesPayable6Member 2020-11-01 2020-12-31 0001119897 PCTL:NotesPayable8Member 2021-06-01 2021-09-30 0001119897 PCTL:NotesPayable9Member 2021-06-01 2021-09-30 0001119897 PCTL:NotesPayable10Member 2021-09-01 2021-09-30 0001119897 PCTL:NotesPayable11Member 2021-09-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty1Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty1Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty1Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty2Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty2Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty2Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty3Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty3Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty3Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty4Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty4Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty4Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty5Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty5Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty5Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty6Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty6Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty6Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty7Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty7Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty7Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty8Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty8Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty8Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty9Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty9Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty9Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty10Member 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty10Member 2021-01-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty10Member 2020-12-31 0001119897 PCTL:NotesPayableRelatedPartyTotalMember 2021-09-30 0001119897 PCTL:NotesPayableRelatedPartyTotalMember 2020-12-31 0001119897 PCTL:NotesPayableRelatedParty2Member 2021-05-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty3Member 2021-05-01 2021-09-30 0001119897 PCTL:NotesPayableRelatedParty3Member 2021-02-16 0001119897 PCTL:ConvertibleNotePayable1Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable1Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable1Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable2Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable2Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable2Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable3Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable3Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable3Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable4Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable4Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable4Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable5Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable5Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable5Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable6Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable6Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable6Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable7Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable7Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable7Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable8Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable8Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable8Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable9Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable9Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable9Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable10Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable10Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable10Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable11Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable11Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable11Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable12Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable12Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable12Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable13Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable13Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable13Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable14Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable14Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable14Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable15Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable15Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable15Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable16Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable16Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable16Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable17Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable17Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable17Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayable18Member 2021-09-30 0001119897 PCTL:ConvertibleNotePayable18Member 2021-01-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable18Member 2020-12-31 0001119897 PCTL:ConvertibleNotePayableTotalMember 2021-09-30 0001119897 PCTL:ConvertibleNotePayableTotalMember 2020-12-31 0001119897 PCTL:ConvertibleNotePayable3Member 2021-08-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable4Member 2020-04-10 0001119897 PCTL:ConvertibleNotePayable4Member 2020-04-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable4Member 2020-01-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable6Member 2020-09-22 0001119897 PCTL:ConvertibleNotePayable6Member 2020-09-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable8Member 2020-10-07 0001119897 PCTL:ConvertibleNotePayable8Member 2020-10-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable9Member 2020-10-16 0001119897 PCTL:ConvertibleNotePayable9Member 2020-10-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable10Member 2020-11-11 0001119897 PCTL:ConvertibleNotePayable10Member 2020-11-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable11Member 2020-12-29 0001119897 PCTL:ConvertibleNotePayable11Member 2020-12-01 2020-12-31 0001119897 PCTL:ConvertibleNotePayable12Member 2021-01-27 0001119897 PCTL:ConvertibleNotePayable13Member 2021-02-22 0001119897 PCTL:ConvertibleNotePayable13Member 2021-05-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable14Member 2021-03-18 0001119897 PCTL:ConvertibleNotePayable14Member 2021-06-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable15Member 2021-03-26 0001119897 PCTL:ConvertibleNotePayable15Member 2021-06-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable16Member 2021-04-05 0001119897 PCTL:ConvertibleNotePayable16Member 2021-07-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable17Member 2021-04-14 0001119897 PCTL:ConvertibleNotePayable17Member 2021-07-01 2021-09-30 0001119897 PCTL:ConvertibleNotePayable18Member 2021-05-03 0001119897 PCTL:ConvertibleNotePayable18Member 2021-08-01 2021-09-30 0001119897 2020-01-01 2020-12-31 0001119897 us-gaap:TradingLiabilitiesMember 2021-01-01 2021-09-30 0001119897 2018-03-23 0001119897 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001119897 2018-12-01 2018-12-31 0001119897 us-gaap:SeriesAPreferredStockMember 2019-04-12 0001119897 us-gaap:SeriesBPreferredStockMember 2019-08-13 0001119897 srt:ChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001119897 srt:ChiefFinancialOfficerMember 2019-01-01 2019-12-31 0001119897 2019-01-01 2019-12-31 0001119897 us-gaap:SeriesCPreferredStockMember 2019-09-18 0001119897 2019-10-04 0001119897 2021-01-04 0001119897 2021-02-16 0001119897 2021-03-01 2021-05-31 0001119897 PCTL:StockIssuedForCash1Member 2021-07-01 2021-09-30 0001119897 PCTL:StockIssuedForCash2Member 2021-07-01 2021-09-30 0001119897 us-gaap:StockOptionMember 2021-09-30 0001119897 us-gaap:StockOptionMember 2021-01-01 2021-09-30 0001119897 us-gaap:WarrantMember 2021-09-30 0001119897 us-gaap:WarrantMember 2021-01-01 2021-09-30 0001119897 PCTL:Warrant1Member 2021-09-30 0001119897 PCTL:Warrant1Member 2021-01-01 2021-09-30 0001119897 PCTL:Warrant2Member 2021-09-30 0001119897 PCTL:Warrant2Member 2021-01-01 2021-09-30 0001119897 2021-08-05 2021-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 10-Q

 

  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

or 

 

  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission file number: 000-31549

 

PCT LTD

(Exact name of registrant as specified in its charter)

 

Nevada 90-0578516
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
   

4235 Commerce Street

Little River, South Carolina

 

29566

(Address of principal executive offices) (Zip Code)

(843) 390-7900

(Registrant's telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
None N/A N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☑ No ☐ The registrant does not have a Web site.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐

Non-accelerated filer

Accelerated filer ☐

Smaller reporting company

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☐ No

 

The number of shares outstanding of the registrant's common stock as of November 15, 2021 was 795,501,229 which does not include 204,123,771 shares of common stock reserved against default on convertible debt and 750,000 shares for vesting of executive shares.

 

 
 

 

TABLE OF CONTENTS

 

Part I - Financial Information Page
     
Item 1. Condensed Consolidated Financial Statements (Unaudited) 3
     
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 26
     
Item 3.  Quantitative and Qualitative Disclosures About Market Risk  29
     
Item 4. Controls and Procedures 29
     
Part II - Other Information  
     
Item 1.  Legal Proceedings  30
     
Item 1A.  Risk Factors  30
     
Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds  30
     
Item 3.   Defaults Upon Senior Securities  31
     
Item 4.  Mine Safety Disclosures  31
     
Item 5. Other Information 31
     
Item 6. Exhibits 32
     
  Signatures 33

  

 

PART I - FINANCIAL INFORMATION

 

 

 

ITEM 1. FINANCIAL STATEMENTS

 

The financial information set forth below with respect to our statements of operations, stockholders' equity (deficit), and cash flows for the three and nine-month periods ended September 30, 2021 and 2020 is unaudited. This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data. The results of operations for the three and nine-month periods ended September 30, 2021 and 2020 are not necessarily indicative of results to be expected for any subsequent period.

 

  3  

 

PCT LTD

Condensed Consolidated Balance Sheets

 

   

September 30,

2021

  December 31,
2020
      (Unaudited)          
ASSETS                
CURRENT ASSETS                
Cash and cash equivalents   $ 239,327     $ 115,196  
Accounts receivable, net     163,147       349,526  
Inventory     12,318       6,188  
Prepaid expenses     168,136       274,736  
Other current assets     18,850       2,110  
Total current assets     601,778       747,756  
                 
PROPERTY AND EQUIPMENT                
Property and equipment, net     320,131       358,719  
                 
OTHER ASSETS                
Intangible assets, net     3,171,658       3,400,024  
Operating lease right-of-use asset     92,772       118,385  
Deposits     -       9,726  
Total other assets     3,264,430       3,528,135  
                 
TOTAL ASSETS   $ 4,186,339     $ 4,634,610  
                 
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT                
CURRENT LIABILITIES                
Accounts payable   $ 60,854     $ 272,978  
Accrued expenses - related parties     82,038       139,280  
Accrued expenses     707,450       622,040  
Deferred revenue     1,075       1,075  
Advances payable     1,450,000       -  
Current portion of operating lease liability     40,127       34,965  
Current portion of notes payable - related parties, net     154,271       789,214  
Current portion of notes payable, net     231,504       384,380  
Current portion of convertible notes payable, net     1,876,338       1,554,503  
Derivative liability     1,561,420       7,102,801  
Total current liabilities     6,165,077       10,901,236  
                 
LONG-TERM LIABILITIES                
 Convertible notes payable, net of current portion and discounts     -       53,500  
 Operating lease liability, net of current portion     52,645       83,420  
                 
TOTAL LIABILITIES   $ 6,217,722       11,038,156  
                 
MEZZANINE EQUITY                
Preferred series A stock, $0.001 par value; 1,000,000 authorized; 500,000 and 500,000 issued and outstanding at September 30, 2021 and December 31, 2020, respectively     60,398       60,398  
Preferred series B stock, $0.001 par value; 1,000,000 authorized; 1,000,000 and 1,000,000 issued and outstanding at September 30, 2021 and December 31, 2020, respectively     158,247       158,247  
Preferred series C stock, $0.001 par value; 5,500,000 authorized; nil and 40,000 issued and outstanding at September 30, 2021 and December 31, 2020, respectively     -       40,000  
TOTAL MEZZANINE EQUITY     218,645       258,645  
                 
STOCKHOLDERS' DEFICIT                
CCommon stock, $0.001 par value; 1,000,000,000 authorized; 780,126,229 and 722,487,846 issued and outstanding at September 30, 2021 and December 31, 2020, respectively     780,126       722,488  
Additional paid-in-capital     24,349,886       23,202,933  
Accumulated deficit     (27,380,040 )     (30,587,612 )
TOTAL STOCKHOLDERS' DEFICIT     (2,250,028 )     (6,662,191 )
                 
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' DEFICIT   $ 4,186,339     $ 4,634,610  

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  4  

 

PCT LTD

Condensed Consolidated Statements of Operations

(Unaudited)

         
   

For the Three Months Ended 

September 30,

 

For the Nine Months Ended

September 30,

    2021   2020   2021   2020
REVENUES                
Product   $ 33,279     $ 488,021     $ 204,138     $ 1,233,058  
Licensing     75,347       119,000       225,122       203,000  
Equipment leases     258,104       177,067       802,132       501,384  
Total Revenues     366,730       784,088       1,231,392       1,937,442  
                                 
OPERATING EXPENSES                                
General and administrative     1,031,072       614,667       2,583,139       1,755,495  
Research and development     14,783       15,547       29,738       20,547  
Cost of product, licensing and equipment leases     85,591       54,901       225,960       619,606  
Depreciation and amortization     98,364       90,999       295,092       255,368  
Total operating expenses     1,229,810       776,114       3,133,929       2,651,016  
                                 
Income (loss) from operations     (863,080 )     7,974       (1,902,537 )     (713,574 )
                                 
OTHER INCOME (EXPENSE)                                
Gain (loss) on change in fair value of derivative liability     457,116       57,054       1,749,277       (15,253,543 )
Gain (loss) on settlement of debt     361,357       (3,670,393 )     3,689,055       9,993,528  
Interest expense     (101,580 )     (200,593 )     (378,223 )     (1,094,934 )
Miscellaneous income     -       -       50,000       -  
Total other income (expense)     716,893       (3,813,932 )     5,110,109       (6,354,949 )
                                 
Income (loss) before Income taxes     (146,187     (3,805,958 )     3,207,572       (7,068,523 )
                                 
Income taxes     -       -       -       -  
                                 
NET INCOME (LOSS)   $ (146,187   $ (3,805,958 )   $ 3,207,572     $ (7,068,523 )
Preferred series C stock deemed dividends     -       -       -       (270,000 )
NET INCOME (LOSS) ATTRIBUTABLE TO COMMON STOCKHOLDERS'   $ (146,187   $ (3,805,958 )   $ 3,207,572     $ (7,338,523 )
                                 
Basic income (loss) per share   $ (0.00   $ (0.01 )   $ 0.00     $ (0.01 )
Diluted income (loss) per share   $ (0.00 )   $ (0.01 )   $ (0.00 )   $ (0.01 )
                                 
Basic weighted average shares outstanding     773,082,751       608,601,357       760,229,694       575,094,639  
Diluted weighted average shares outstanding     773,082,751       608,601,357       1,024,432,537       575,094,639  

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  5  

 

PCT LTD

Condensed Consolidated Statements of Stockholders' Equity (Deficit)

For the Three and Nine Months Ended September 30, 2021 and 2020

(Unaudited)   

                     
            Additional       Total Stockholders'
    Common Stock   Paid-in   Accumulated   Equity
    Shares   Amount   Capital   Deficit   (Deficit)
Balance - December 31, 2019     498,880,300     $ 498,881     $ 15,872,330     $ (26,505,567 )   $ (10,134,356 )
Common stock issued for services     15,525,000       15,525       103,538       -       119,063  
Common stock issued in settlement of debt     250,000       250       7,975       -       8,225  
Common stock issued in conversion of convertible notes payable     36,050,000       36,050       360,660       -       396,710  
Beneficial conversion feature on preferred series C stock     -       -       270,000       (270,000 )     -  
Net loss for the three-months ended March 31, 2020     -       -       -       (10,281,648 )     (10,281,648 )
Balance - March 31, 2020     550,705,300     $ 550,706     $ 16,614,503     $ (37,057,215 )   $ (19,892,006 )
Common stock issued for cash     4,250,000       4,250       135,750       -       140,000  
Common stock issued in settlement of debt     15,000,000       15,000       826,500       -       841,500  
Common stock issued in cashless exercise of warrants     9,246,186       9,246       420,702       -       429,948  
Common stock issued in conversion of preferred series C stock     5,000,000       5,000       45,000       -       50,000  
Stock-based compensation     -       -       14,182       -       14,182  
Net income for the three-months ended June 30, 2020     -       -       -       7,019,083       7,019,083  
Balance - June 30, 2020     584,201,486     $ 584,202     $ 18,056,637     $ (30,038,132 )   $ (11,397,293 )
Common stock issued for services     10,000,000       10,000       384,038       -       394,038  
Common stock issued in conversion of convertible notes payable     45,736,360       45,736       497,222       -       542,958  
Common stock issued in conversion of preferred series C stock     35,000,000       35,000       359,000       -       394,000  
Premium related to conversion feature on note payable     -       -       4,160,685       -       4,160,685  
Net loss for the three-months ended September 30, 2020     -       -       -       (3,805,958 )     (3,805,958 )
Balance - September 30, 2020     674,937,846     $ 674,938     $ 23,457,582     $ (33,844,090 )   $ (9,711,570 )
                                         
                                         
            Additional       Total Stockholders'
    Common Stock   Paid-in   Accumulated   Equity
    Shares   Amount   Capital   Deficit   (Deficit)
Balance - December 31, 2020     722,487,846     $ 722,488     $ 23,202,933     $ (30,587,612 )   $ (6,662,191 )
Common stock issued for services     2,500,000       2,500       74,276       -       76,776  
Common stock issued in settlement of debt     4,466,508       4,466       648,844       -       653,310  
Common stock issued in conversion of convertible notes payable     25,000,000       25,000       -       -       25,000  
Common stock issued in conversion of preferred series C stock     4,000,000       4,000       36,000       -       40,000  
Net loss for the three-months ended March 31, 2021     -       -       -       (718,028 )     (718,028 )
Balance - March 31, 2021     758,454,354     $ 758,454     $ 23,962,053     $ (31,305,640 )   $ (6,585,133 )
Common stock issued for cash     8,750,000       8,750       166,250       -       175,000  
Common stock issued for services     1,000,000       1,000       32,174       -       33,174  
Common stock issued in cashless exercise of warrants     1,921,875       1,922       32,672       -       34,594  
Net income for the three-months ended June 30, 2021     -       -       -       4,071,787       4,071,787  
Balance - June 30, 2021     770,126,229     $ 770,126     $ 24,193,149     $ (27,233,853 )   $ (2,270,578 )
Common stock issued for services     2,000,000       2,000       40,737       -       42,737  
Common stock issued in conversion of convertible notes payable     8,000,000       8,000       116,000       -       124,000  
Net loss for the three-months ended September 30, 2021     -       -       -       (146,187     (146,187
Balance - September 30, 2021     780,126,229     $ 780,126     $ 24,349,886     $ (27,380,040 )     (2,250,028 )

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

  6  

 

PCT LTD

Condensed Consolidated Statements of Cash Flows

(Unaudited)

     
   

For the Nine Months Ended

September 30,

    2021   2020
Cash Flows from Operating Activities                
Net loss   $ 3,207,572     $ (7,068,523 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Depreciation and amortization     295,092       255,368  
Amortization of debt discounts     240,413       353,012  
Amortization of operating lease right-of-use asset     39,182       -  
Common stock issued for services     267,830       527,283  
Loss on change in fair value of derivative liability     (1,749,277 )     15,253,543  
(Gain) loss on settlement of debt     (3,689,055 )     (9,993,528 )
Default penalties on convertible notes payable     15,172       13,762  
Bad debt expense     182,700       -  
Changes in operating assets and liabilities:                
Accounts receivable     3,679       (157,076 )
Inventory     (6,130 )     26,669  
Prepaid expenses     (8,543 )     (241,764 )
Other assets     (16,740 )     (3,853 )
Deposits     9,726          
Operating lease liability     (39,182 )     -  
Accounts payable     (212,125 )     (87,369 )
Accrued expenses - related party     14,887       27,071  
Accrued expenses     165,479       807,049  
Net cash used in operating activities     (1,279,320 )     (288,356 )
                 
Cash Flows from Investing Activities                
Purchases of property and equipment     (28,138 )     (127,212 )
Net cash provided by investing activities     (28,138 )     (127,212 )
                 
Cash Flows from Financing Activities                
Proceeds from notes payable - related parties     -       3,500  
Proceeds from notes payable     410,377       428,030  
Proceeds from convertible notes payable     920,000       613,000  
Proceeds from advances payable     1,450,000       -  
Proceeds from sale of common stock     175,000       140,000  
Proceeds from preferred series C stock subscriptions     -       270,000  
Repayments of notes payable - related parties     (53,763 )     (32,286 )
Repayments of notes payable     (796,036 )     (556,153 )
Repayments of convertible notes payable     (673,989 )     (356,888 )
Net cash provided by financing activities     1,431,589       509,203  
                 
Net change in cash     124,131       93,635  
Cash and cash equivalents at beginning of period     115,196       67,613  
Cash and cash equivalents at end of period   $ 239,327     $ 161,248  
                 
Supplemental Cash Flow Information                
Cash paid for interest   $ 72,763     $ 77,687  
Cash paid for income taxes   $ -     $ -  
                 
Non-Cash Investing and Financing Activities:                
Preferred series C stock deemed dividend   $ -     $ 270,000  
Original debt discounts against notes payable   $ 174,435     $ 95,562  
Original debt discounts against convertible notes payable   $ 12,000     $ 201,388  
Common stock issued for services   $ 81,740     $ -  
Common stock issued in conversion of convertible notes payable   $ 149,000     $ 939,668  
Common stock issued in settlement of notes payable to related parties     653,310       -  
Common stock issued in cashless exercise of warrants   $ 34,594     $ 429,948  
Common stock issued in conversion of preferred series C stock   $ 40,000     $ 444,000  
Property plant and equipment transferred to inventory   $ -     $ 26,669  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

  7  

 

PCT LTD

Notes to the Unaudited

Condensed Consolidated Financial Statements

September 30, 2021

 

NOTE 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

The unaudited interim condensed consolidated financial statements of PCT LTD (the "Company") have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and reflect all adjustments which, in the opinion of management, are necessary for a fair presentation of our balance sheets, statements of operations, stockholders' equity (deficit), and cash flows for the periods presented. All such adjustments are of a normal recurring nature. The results of operations for the interim period are not necessarily indicative of the results to be expected for a full year.

 

Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these condensed consolidated financial statements be read in conjunction with the financial statements and notes thereto included in the Company's December 31, 2020 audited financial statements as reported in its Form 10-K/A filed on September 10, 2021.

 

COVID-19

 

In December 2019 COVID-19 emerged in Wuhan, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to almost all other countries, including the United States, and infections have been reported globally. Because COVID-19 infections have been reported throughout the United States, certain federal, state and local governmental authorities have issued stay-at-home orders, proclamations and/or directives aimed at minimizing the spread of COVID-19. Additional, more restrictive proclamations and/or directives may be issued in the future.

 

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. The significance of the impact of the COVID-19 outbreak on the Company's businesses and the duration for which it may have an impact cannot be determined at this time. At a minimum, the COVID-19 pandemic caused the Company to restrict travel of its personnel and to initiate distributor installations of certain of the Company's equipment, as possible. The Company adapted to the immediate need for its US EPA registered disinfectant at the end of March and beginning of April, 2020, by installing greater storage reserves and by assembling more of it higher-volume equipment to produce the hospital grade disinfectant known as Hydrolyte®. There were hard costs associated with these adaptations to the Little River, SC facility, but the Company continues to benefit from its fluid production capacities over the longer term. As the Federal, state and other restrictions associated with the pandemic have lessened, the Company is able to act more effectively in obtaining new contracts for its healthcare equipment, the Annihilyzer® and other equipment.

 

Nature of Operations

 

PCT LTD (formerly Bingham Canyon Corporation, (the "Company," "PCT Ltd," or "Bingham"), a Delaware corporation, was formed on February 27, 1986. The Company changed its domicile to Nevada on August 26, 1998. The Company acquires, develops and provides sustainable, environmentally safe disinfecting, cleaning and tracking technologies. The Company specializes in providing cleaning, sanitizing, and disinfectant fluid solutions and fluid-generating equipment that creates environmentally safe solutions for global sustainability.

 

Paradigm is located in Little River, SC and was formed June 6, 2012 under the name of EUR-ECA, Ltd. On September 11, 2015, its Board of Directors authorized EUR-ECA Ltd to file with the Nevada Secretary of State to change its name to Paradigm Convergence Technologies Corp. Paradigm is a technology licensing company specializing in environmentally safe solutions for global sustainability. The company holds a patent, intellectual property and/or distribution rights to innovative products and technologies. Paradigm provides innovative products and technologies for eliminating biocidal contamination from water supplies, industrial fluids, hard surfaces, food processing equipment, and medical devices. Paradigm's overall strategy is to market new products and technologies through the use of equipment leasing, joint ventures, licensing, distributor agreements and partnerships.

 

Effective on February 29, 2018, the Company changed its name from Bingham Canyon Corporation to PCT LTD to more accurately identify the Company's direction and to develop the complimentary relationship and association with its wholly-owned operating company, Paradigm Convergence Technologies Corporation ("Paradigm" or "PCT Corp.").

  8  

 

 

Significant Accounting Policies

 

There have been no changes to the significant accounting policies of the Company from the information provided in Note 1 of the Notes to the Consolidated Financial Statements in the Company's most recent Form 10-K.

 

Fair Value Measurements

 

The Company follows ASC 820, "Fair Value Measurements and Disclosures", which defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last is considered unobservable, is used to measure fair value:

 

  Level 1 - Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.

 

  Level 2 - Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

 

  Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

 

The carrying values of our financial instruments, including, cash and cash equivalents, accounts receivable, inventory, prepaid expenses, accounts payable and accrued expenses approximate their fair value due to the short maturities of these financial instruments.

 

Derivative liabilities are determined based on "Level 3" inputs, which are significant and unobservable and have the lowest priority. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

 

Our financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2021, consisted of the following:

 

    Total fair value at
September 30,
2021
$
  Quoted prices in active markets
(Level 1)
$
  Significant other observable inputs
(Level 2)
$
  Significant unobservable inputs
(Level 3)
$
Description:                                
Derivative liability (1)     1,561,420       -       -       1,561,420  
Total     1,561,420       -       -       1,561,420  

 

Our financial assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2020, consisted of the following:

 

    Total fair value at
December 31,
2020
$
  Quoted prices in active markets
(Level 1)
$
  Significant other observable inputs
(Level 2)
$
  Significant unobservable inputs
(Level 3)
$
Description:                                
Derivative liability (1)     7,102,801       -       -       7,102,801  
Total     7,102,801       -       -       7,102,801  

 

(1) The Company has estimated the fair value of these liabilities using the Binomial Model.

 

  9  

 

Basic and Diluted Loss Per Share

 

Basic income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding during the period.  Diluted income (loss) per share is computed by dividing net income (loss) by the weighted-average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as options, warrants, convertible notes payable, preferred series A stock and preferred series C stock. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, for the nine months ended September 30, 2021, there were outstanding common share equivalents which amounted to 18,902,412 shares of common stock that were not included in the calculation as their effect is anti-dilutive. For fiscal periods with net losses, these common share equivalents were not included in the computation of diluted loss per share as their effect would have been anti-dilutive.

 

    Three months ended September 30, 2021
$
  Three months ended September 30, 2020
$
  Nine months
ended September 30, 2021
$
  Nine months
ended September 30, 2020
$
Numerator:                                
Net income (loss)     (146,187     (3,805,958 )     3,207,572       (7,338,523 )
(Gain) loss on change in fair value of derivative liability     -     -       (1,641,616 )     -  
Gain on settlement of debt     -     -       (3,792,104 )     -  
Interest expense     -       -       30,617       -  
Adjusted net income (loss)     (146,187 )     (3,805,958 )     (2,195,531 )     (7,338,523 )
                                 
Denominator: Weighted average shares outstanding used in computing net income (loss) per share                                
Basic     773,082,751       608,601,357       760,229,694       575,094,639  
                                 
Effect of dilutive warrants     -       -       203,745,854       -  
Effect of convertible note weighted shares     -       -       60,456,989       -  
Diluted     773,082,751       608,601,357       1,024,432,537       575,094,639  
                                 
Net income (loss) per share applicable to common shareholders:                                
Basic     (0.00     (0.01 )     (0.00     (0.01 )
Diluted     (0.00 )     (0.01 )     (0.00 )     (0.01 )

 

 

Recent Accounting Pronouncements 

 

ASU 2019-12 amends the requirements related to the accounting for "hybrid" tax regimes. Such regimes are tax jurisdictions that impose the greater of two taxes - one based on income, or one based on items other than income. Although ASC 740 does not apply to taxes based on items other than income, ASC 740-10-15-4(a) originally specified that if there is a tax based on income that is greater than a franchise tax based on capital, only that excess is subject to the guidance in ASC 740. In feedback to the FASB, stakeholders indicated that the guidance on hybrid tax regimes increased the cost and complexity of applying ASC 740, particularly when the tax amount deemed to be a non-income tax was insignificant. Further, such guidance made it more difficult for entities to determine the appropriate tax rate to use when recording deferred taxes.

 

Accordingly, the FASB amended ASC 740-10-15-4(a) to state that an entity should include the amount of tax based on income in the tax provision and should record any incremental amount recorded as a tax not based on income. This amendment effectively reverses the order in which an entity determines the type of tax under current U.S. GAAP. In addition, the ASU amends the illustrative examples referred to and included in ASC 740-10-55-26 and ASC 740-10-55-139 through 55-144. The FASB notes that such amendments are consistent with the accounting for other incremental taxes, such as the base erosion anti-abuse tax. Moreover, in paragraph BC12 of the ASU, the FASB concluded that subjecting these taxes to the disclosure requirements in ASC 740 will result in greater transparency of franchise tax amounts.

 

  10  

 

In August 2020, the FASB issued ASU 2020-06, "Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815- 40)" ("ASU 2020-06"). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity's own equity. The ASU is part of the FASB's simplification initiative, which aims to reduce unnecessary complexity in U.S. GAAP. The ASU's amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently evaluating the impact ASU 2020-06 will have on its financial statements. 

 

 

NOTE 2. GOING CONCERN

 

The accompanying consolidated condensed financial statements have been prepared assuming that the Company will continue as a going concern. The Company has an accumulated deficit of $27,380,040 and has negative cash flows from operations. As of September 30, 2021, the Company had a working capital deficit of $5,563,299. The Company has relied on raising debt and equity capital in order to fund its ongoing day-to-day operations and its corporate overhead. The Company will require additional working capital from either cash flow from operations, from debt or equity financing, or from a combination of these sources. These factors raise substantial doubt about the ability of the Company to continue as a going concern for a period of one year from the issuance of these financial statements. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

 

NOTE 3. PROPERTY AND EQUIPMENT

 

Property and equipment at September 30, 2021 and December 31, 2020 consisted of the following: 

 

    September 30, 2021   December 31, 2020
Leasehold improvements   $ 33,770     $ 18,840  
Machinery and leased equipment     365,483       365,483  
Machinery and equipment not yet in service     32,580       32,580  
Office equipment and furniture     52,566       39,357  
Website     2,760       2,760  
                 
Total property and equipment   $ 487,159     $ 459,020  
Less: Accumulated Depreciation     (167,028 )     (100,301 )
                 
Property and equipment, net     320,131       358,719  

 

Depreciation expense was $66,726 and $27,085 for the nine-months ended September 30, 2021 and 2020, respectively.

 

 

NOTE 4. INTANGIBLE ASSETS

 

Intangible assets at September 30, 2021 and December 31, 2020 consisted of the following:

 

    September 30, 2021   December 31, 2020
Patents   $ 4,505,489     $ 4,505,489  
Technology rights     200,000       200,000  
Intangibles, at cost     4,705,489       4,705,489  
Less: Accumulated amortization     (1,533,831 )     (1,305,465 )
Net Carrying Amount   $ 3,171,658     $ 3,400,024  

 

Amortization expense was $228,366 and $228,283 for the nine-months ended September 30, 2021 and 2020, respectively.

 

Estimated Future Amortization Expense:

 

    $  
For year ending December 31, 2021 - remaining     76,122  
For year ending December 31, 2022     304,488  
For year ending December 31, 2023     304,488  
For year ending December 31, 2024     304,488  
For year ending December 31, 2025     304,488  
Thereafter     1,877,584  
Total     3,171,658  

 

 

  11  

 

NOTE 5. LEASES

 

On August 26, 2020, the Company signed a new one-year lease for the Company headquarters and operations located in Little River, South Carolina. The lease was effective retroactively from July 1, 2020, ending on June 30, 2021, for $7,500 per month. The Company re-negotiated an annual lease on the Little River, SC facility for $7,500 per month, retroactive to July 1, 2020, which is renewable for an additional four years (with a 2% increase annually). The Company renewed the lease for another year, effective July 1, 2021, at $7,650 per month.

 

On October 19, 2020, the Company entered into a building lease with a three-year term and an effective date of November 1, 2020. The lease requires the Company to make payments of $4,500 per month. The Company recognized operating lease expense of $40,500 during the nine-month period ended September 30, 2021.

 

On March 15, 2021, the Company entered into a building lease with a two-year term and an effective date of April 1, 2021. The lease requires the Company to make payments of $2,750 per month. The Company recognized operating lease expense of $19,250 during the nine-month period ended September 30, 2021. The Company terminated the lease effective October 14, 2021 and recognized an impairment of $39,030 during the nine-month period ended September 30, 2021.

 

At September 30, 2021, the weighted average remaining operating lease term was 2.07 years and the weighted average discount rate associated with operating leases was 18.5%.

 

The components of lease expenses for the nine-month period ended September 30, 2021 and 2020 were as follows:

 

   

2021

$

 

2020

$

Total operating lease cost     59,750       -  

The following table provides supplemental cashflow and other information related to leases for the nine-month period ended September 30, 2021 and 2020:

 

   

2021

$

 

2020

$

Lease payments     127,700       40,440  

Supplemental balance sheet information related to leases as of September 30, 2021 and 2020 are as below:

 

   

2021

$

 

2020

$

Cost     176,213       -  
Accumulated amortization     (44,411 )     -  
Impairment     (39,030 )        
Net carrying value     92,772       -  

 

Future minimum lease payments related to lease obligations are as follows as of September 30, 2021:

 

    $
2021     13,500  
2022     54,000  
2023     45,000  
Total minimum lease payments     112,500  
         
Less: amount of lease payments representing effects of discounting     (19,728 )
         
Present value of future minimum lease payments     92,772  
         
Less: current obligations under leases     (40,127 )
         
Lease liabilities, net of current portion     52,645  

 

  12  

 

 

NOTE 6. NOTES PAYABLE 

 

The following tables summarize notes payable as of September 30, 2021 and December 31, 2020:

 

Type   Original Amount  

Origination

Date

 

Maturity

Date

 

Effective Annual

Interest

Rate

 

Balance at

September 30, 2021

 

Balance at

December 31, 2020

Note Payable (a)**   $ 25,000     05/08/2017   06/30/2018     0 %   $ 22,500     $ 27,500  
Note Payable (b)   $ 8,700     11/15/2018   06/30/2019     10 %   $ -       $ 8,700  
Note Payable **   $ 118,644     05/05/2020   05/05/2021     8 %   $ 110,644     $ 110,644  
Note Payable (c)   $ 199,500     10/01/2020   09/28/2021     66 %   $ -       $ 149,573  
Note Payable (d)   $ 126,000     11/03/2020   04/23/2021     166 %   $ -       $ 85,050  
Note Payable (e)   $ 113,980     11/04/2020   03/15/2021     210 %   $ -       $ 65,988  
Note Payable (f)   $ 177,800     01/02/2021   07/12/2021     116 %   $ -       $ -    
Note Payable (g)   $ 111,920     03/09/2021   05/21/2021     220 %   $ -       $ -    
Note Payable (h)   $ 29,686     03/09/2021   Demand     34 %   $ -       $ -    
Note Payable (i)   $ 222,400     06/01/2021   Demand     181 %   $ 76,985     $ -    
Note Payable (j)   $ 87,000     06/29/2021   Demand     211 %   $ 31,320     $ -    
Sub-total                           $ 241,449     $ 447,455  
Debt discount                           $ (9,945 )   $ (63,075 )
Balance, net                           $ 231,504     $ 384,380  
Less current portion                           $ (231,504 )   $ (384,380 )
Total long-term                           $       $    
                                         
** Currently in default

 

  a) On July 19, 2021, the Company repaid the principal amount of $5,000 leaving a note balance of $22,500.

 

  b) On July 19, 2021, the Company repaid the principal amount of $8,700 leaving a note balance of $0.

 

  c) On October 1, 2020, the Company sold future receivables with a non-related party for $199,500, of which $53,250 was loan fees and original issue discount resulting in cash proceeds to the Company of $146,250. The advance is to be repaid through weekly payments of $3,841. In connection with the advance, the Company granted the lender a security interest and all past, present and future assets of the Company. During the nine months ended September 30, 2021, $30,642 of the discount was amortized to expense, and the note was repaid leaving a note balance of $0.

 

  d) On November 3, 2020, the Company sold future receivables with a non-related party for $126,000, of which $39,650 was loan fees and original issue discount resulting in cash proceeds to the Company of $86,350. The advance is to be repaid through $1,050 daily payments. In connection with the advance, the Company granted the lender a security interest and all past, present and future assets of the Company. During the nine months ended September 30, 2021, $18,944 of the discount was amortized to expense, and the remaining $85,050 was repaid leaving a note balance of $0.

 

  e) On November 4, 2020, the Company sold future receivables with a non-related party for $113,980, of which $34,440 was loan fees and original issue discount resulting in cash proceeds to the Company of $79,540. The advance is to be repaid through $5,999 weekly payments. In connection with the advance, the Company granted the lender a security interest and all past, present and future assets of the Company. During the nine months ended September 30, 2021, $13,489 of the discount was amortized to expense, and the remaining $65,988 was repaid leaving a note balance of $0.

 

  f) On January 2, 2021, the Company sold future receivables with a non-related party for $177,800, of which $39,795 was loan fees and original issue discount resulting, and $35,994 was paid to settle the loan described in Note (d) in cash proceeds to the Company of $102,011. The advance is to be repaid through $7,730 weekly payments. In connection with the advance, the Company granted the lender a security interest and all past, present and future assets of the Company. During the nine months ended September 30, 2021, $39,795 of the discount was amortized to expense, and the remaining $46,383 was settled through a payment of $43,600 resulting in a gain on settlement of debt of $2,783 and a note balance of $0.

 

  13  

 

  g) On March 9, 2021, the Company sold future receivables with a non-related party for $111,920, of which $35,120 was loan fees and original issue discount resulting in cash proceeds to the Company of $76,800. The advance is to be repaid through $1,399 weekly payments. In connection with the advance, the Company granted the lender a security interest and all past, present and future assets of the Company. During the nine months ended September 30, 2021, $35,120 of the discount was amortized to expense, and $111,920 was repaid leaving a note balance of $0.

 

h) On March 9, 2021, the Company sold future receivables with a non-related party for $29,686, of which $10,120 was loan fees and original issue discount resulting in cash proceeds to the Company of $19,566. During the six months ended September 30, 2021, $10,120 of the discount was amortized to expense and $29,686 was repaid, leaving a note balance of $0.

 

i) On June 1, 2021, the Company sold future receivables with a non-related party for $222,400, of which $8,000 was attributable to loan fees and $62,400 to original issue discount resulting in cash proceeds to the Company of $152,000. The advance is to be repaid through weekly payments of $8,554. In connection with the advance, the Company granted the lender a security interest and all past, present, and future assets of the Company. During the nine months ended September 30, 2021, $64,414 of the discount was amortized to expense, and $145,415 was repaid leaving a net note balance of $70,999 (discount balance of $5,986).

 

j) On June 29, 2021, the Company sold future receivables with a non-related party for $87,000, of which $27,000 was loan fees and original issue discount resulting in cash proceeds to the Company of $60,000. During the nine months ended September 30, 2021, $23,041 of the discount was amortized to expense, and $55,680 was repaid leaving a net note balance of $27,361 (discount balance of $3,959).

 

The following table summarizes notes payable, related parties as of September 30, 2021 and December 31, 2020:

 

Type   Original Amount  

Origination

Date

 

Maturity

Date

 

Annual

Interest

Rate

 

Balance at

September 30,

2021

 

Balance at

December 31, 2020

Note Payable, RP (k)   $ 30,000     04/10/2018   01/15/2019     3 %   $ -       $ 30,000  
Note Payable, RP (l)   $ 380,000     06/20/2018   01/02/2020     8 %   $ -       $ 380,000  
Note Payable, RP (m)   $ 350,000     06/20/2018   01/02/2020     5 %   $ -       $ 285,214  
Note Payable, RP (n)**   $ 17,000     06/20/2018   01/02/2020     5 %   $ 15,000     $ 17,000  
Note Payable, RP **   $ 50,000     07/27/2018   11/30/2018     8 %   $ 50,000     $ 50,000  
Note Payable, RP (o)   $ 5,000     10/09/2018   Demand     0 %   $ -       $ 5,000  
Note Payable, RP (p)   $ 5,000     10/19/2018   Demand     0 %   $ 4,237     $ 5,000  
Note Payable, RP **   $ 15,000     08/16/2019   02/16/2020     8 %   $ 15,000     $ 15,000  
Note Payable, RP (q)   $ 2,000     02/11/2020   Demand     0 %   $ -       $ 2,000  
Note Payable, RP (m)   $ 84,034     02/16/2021   Demand     5 %   $ 70,034     $ -    
Subtotal                           $ 154,271     $ 789,214  
Debt discount                           $       $    
Balance, net                           $ 154,271     $ 789,214  
Less current portion                           $ (154,271 )   $ (789,214 )
Total long-term                           $       $    
                                         
** Currently in default

 

  k) During the nine-months ended September 30, 2021, the Company made several payments to repay the principal amount of $30,000 leaving a note balance of $0.

 

  l) On February 16, 2021, the Company issued 2,663,299 shares of common stock to settle a June 20, 2018, note payable of $380,000 and accrued interest of $26,153 owed to the current COO and Director of the Company.  The Company recognized the fair value of the shares issued of $74,572 and due to the related party nature of the transaction no gain was recognized for the difference between the fair value of the shares and the extinguished debt. The resulting difference was recorded as Additional Paid-in Capital in the amount of $328,919.

 

  14  

 

  m) On February 16, 2021, the Company issued 1,803,279 shares of common stock to settle $247,270 from a $275,000 note payable dated June 20, 2018, which has a balance of $331,304, including interest, to the current Chairman and CEO of the Company. The Company also agreed to issue a new note for the remaining balance owed to the Chairman and CEO of $84,034, dated February 16, 2021. The note will bear interest at 5% per annum and is due on June 30, 2021. The Company recognized the fair value of the shares issued of $50,492 and due to the related party nature of the transaction no gain was recognized for the difference between the fair value of the shares and the extinguished debt. The resulting difference was recorded as Additional Paid-in Capital in the amount of $194,861. On July 15, 2021, and September 23, 2021, the Company repaid the principal amount of $14,000 leaving a note balance of $70,034.

 

  n) On July 15, 2021, the Company repaid the principal amount of $2,000 leaving a note balance of $15,000.

 

  o) On September 23, 2021, the Company repaid the principal amount of $5,000 leaving a note balance of $0.

 

  p) On September 23, 2021, the Company repaid the principal amount of $763 leaving a note balance of $4,237.

 

  q) On September 23, 2021, the Company repaid the principal amount of $2,000 leaving a note balance of $0.

 

 

The following table summarizes convertible notes payable as of September 30, 2021 and December 31, 2020:

 

Type   Original Amount  

Origination

Date

 

Maturity

Date

 

Annual

Interest

Rate

 

Balance at

September 30,

2021

 

Balance at

December 31, 2020

Convertible Note Payable* **   $ 65,000     12/06/2018   12/06/2019     12 %   $ 46     $ 46  
Convertible Note Payable (r)   $ 75,000     03/18/2019   12/13/2019     24 %   $ -       $ 177,795  
Convertible Note Payable (s)   $ 30,000     03/06/2020   03/05/2021     12 %   $ -       $ 21,662  
Convertible Note Payable (t)* ** $ 150,000     04/10/2020   04/09/2021     12 %   $ 65,000     $ 165,000  
Convertible Note Payable (u) **   $ 300,000     08/27/2020   07/31/2021     12 %   $ 270,000     $ 300,000  
Convertible Note Payable (v)   $ 53,500     09/22/2020   03/21/2022     12 %   $ -       $ 53,500  
Convertible Note Payable (w)   $ 87,500     09/24/2020   Demand     8 %   $ 15,000     $ 40,000  
Convertible Note Payable (x)   $ 200,000     10/07/2020   10/06/2021     5 %   $ 200,000     $ 200,000  
Convertible Note Payable (y)   $ 200,000     10/16/2020   10/15/2021     5 %   $ 200,000     $ 200,000  
Convertible Note Payable (z)   $ 300,000     11/11/2020   11/10/2021     5 %   $ 300,000     $ 300,000  
Convertible Note Payable (aa)   $ 150,000     12/29/2020   12/28/2021     5 %   $ 150,000     $ 150,000  
Convertible Note Payable (bb)   $ 150,000     01/27/2021   01/27/2022     5 %   $ 150,000     $ -    
Convertible Note Payable (cc)   $ 128,000     02/22/2021   02/22/2022     12 %   $ -       $ -    
Convertible Note Payable (dd)   $ 200,000     03/18/2021   03/18/2022     5 %   $ 200,000     $ -    
Convertible Note Payable (ee)   $ 83,000     03/26/2021   03/26/2022     12 %   $ -       $ -    
Convertible Note Payable (ff)   $ 43,000     04/05/2021   04/05/2022     12 %   $ -       $ -    
Convertible Note Payable (gg)   $ 200,000     04/14/2021   04/14/2022     5 %   $ 200,000     $ -    
Convertible Note Payable (hh)   $ 128,000     05/03/2021   05/03/2022     12 %   $ 128,000     $ -    
Subtotal                           $ 1,876,046     $ 1,608,003  
Debt discount                           $ (1,708 )   $    
Balance, net                           $ 1,876,338     $ 1,608,003  
Less current portion                           $ (1,876,338 )   $ (1,554,503 )
Total long-term                                     53,500   
* Embedded conversion feature accounted for as a derivative liability at period end
** Currently in default

 

  15  

 

  r) During the nine months ended September 30, 2021, the Company repaid $70,000 of the convertible note payable and settled the remaining outstanding debt of $107,795 and accrued interest of $76,569 through a cash payment of $40,000 and the issuance of 8,000,000 shares of common stock at a fair value of $124,000 resulting in a gain on settlement of debt of $20,364.

 

  s) On May 7, 2021, the Company deemed in the best interest to settle the convertible debt with a non-related party and allow for the cashless exercise to purchase 1,921,875 shares of the Company's common stock at the rate of $0.032 per share. In addition, the non-related party shall release 60,072,853 shares to the agreed upon payment terms of $36,994 cash. During the nine months ended September 30, 2021, the Company incurred additional default penalties of $15,174 on the convertible note and settled the outstanding debt of $36,836 and accrued interest of $3,657 through a cash payment of $36,994 and the cashless exercise to purchase 1,921,875 shares of the Company's common stock with a fair value of $34,594 resulting in a loss on settlement of debt of $31,095.

 

  t)

On April 10, 2020, the Company entered into a convertible promissory note with a non-related party for $150,000, of which $18,000 was an original issue discount resulting in cash proceeds to the Company of $132,000. The note is due on April 9, 2021 and bears interest on the unpaid principal balance at a rate of 12% per annum. The Note may be converted by the Lender at any time into shares of Company's common stock at a conversion price equal to 65% of the lowest trading price during the 25-trading day period prior to the conversion date. Further, if at any time the stock price is less than $0.30, an additional 20% discount is applied and if at any time the conversion price is less than $0.01 an additional 10% is applied. Further, an additional 15% is applied if the Company fails to comply with its reporting requirements. During the period, all these additional discounts were triggered.

 

The embedded conversion option qualified for derivative accounting and bifurcation under ASC 815-15. The initial fair value of the conversion feature was $507,847 and resulted in a discount to the note payable of $132,000 and an initial derivative expense of $375,847. During the year ended December 31, 2020, the Company incurred $15,000 of penalties which increased the principal amount of the note to $165,000. During the nine months ended September 30, 2021, the Company repaid $100,000 of the note, leaving a note balance of $65,000.

 

  u) During the nine months ended September 30, 2021, the Company repaid $30,000 of the note, leaving a note balance of $270,000.

 

  v) On September 22, 2020, the Company entered into a convertible promissory note with a non-related party for $53,500, of which $3,500 was an original issue discount resulting in cash proceeds to the Company of $50,000. The note is due on March 21, 2022 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note's term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date. During the nine months ended September 30, 2021 the Company repaid the $53,500 note as well as $25,882 of interest and prepayment penalties. As the note was repaid prior to becoming convertible no derivative liability was recognized.

 

  w) During the nine months ended September 30, 2021 the Company issued 25,000,000 common shares upon the conversion of $25,000 of the convertible note payable, leaving a note balance of $15,000. On October 11, 2021, the Company issued 15,000,000 common shares upon the conversion of the remaining $15,000 of the convertible note payable. Refer to Note 12(a).

 

  x) On October 7, 2020, the Company entered into a convertible promissory note with a non-related party for $200,000. The note is due on October 6, 2021 and bears interest on the unpaid principal balance at a rate of 5% per annum. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price of $0.20. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  y) On October 16, 2020, the Company entered into a convertible promissory note with a non-related party for $200,000. The note is due on October 15, 2021 and bears interest on the unpaid principal balance at a rate of 5% per annum. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price of $0.20. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  16  

 

  z) On November 11, 2020, the Company entered into a convertible promissory note with a non-related party for $300,000. The note is due on November 10, 2021 and bears interest on the unpaid principal balance at a rate of 5% per annum. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price of $0.15. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  aa) On December 29, 2020, the Company entered into a convertible promissory note with a non-related party for $150,000. The note is due on December 28, 2021 and bears interest on the unpaid principal balance at a rate of 5% per annum. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price of $0.10. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  bb) On January 27, 2021, the Company entered into a convertible promissory note with a non-related party for $150,000. The note is due on January 26, 2022 and bears interest on the unpaid principal balance at a rate of 5% per annum. The note may be converted by the lender at any time before 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to $0.10. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  cc) On February 22, 2021, the Company entered into a convertible promissory note with a non-related party for $128,000, of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $125,000. The note is due on February 22, 2022 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note's term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. During the nine months ended September 30, 2021 the Company repaid the $128,000 note as well as $51,000 of interest and prepayment penalties. As the note was repaid prior to becoming convertible no derivative liability was recognized.

 

  dd) On March 18, 2021, the Company entered into a convertible promissory note with a non-related party for $200,000. The note is due on March 17, 2022 and bears interest on the unpaid principal balance at a rate of 5% per annum. The note may be converted by the lender at any time before 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to $0.10. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. The Company determined that there was no derivative liability associated with the debenture under ASC 815-15 Derivatives and Hedging.

 

  ee) On March 26, 2021, the Company entered into a convertible promissory note with a non-related party for $83,000, of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $80,000. The note is due on March 24, 2022 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note's term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. During the nine months ended September 30, 2021 the Company repaid the $83,000 note as well as $39,694 of interest and prepayment penalties. As the note was repaid prior to becoming convertible no derivative liability was recognized.

 

  ff) On April 5, 2021, the Company entered into a convertible promissory note with a non-related party for $43,000, of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $40,000. The note is due on April 5, 2022 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note's term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. During the nine months ended September 30, 2021 the Company repaid the $43,000 note as well as $12,270 of interest and prepayment penalties. As the note was repaid prior to becoming convertible no derivative liability was recognized.

 

  17  

 

  gg) On April 14, 2021, the Company entered into a convertible promissory note with a non-related party for $200,000. The note is due on April 14, 2022 and bears interest on the unpaid principal balance at a rate of 5% per annum. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price of $0.10. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. As the note is not convertible until 180 days following issuance, no derivative liability was recognized as of September 30, 2021.

 

  hh) On May 3, 2021, the Company entered into a convertible promissory note with a non-related party for $128,000, of which $3,000 was an original issue discount resulting in cash proceeds to the Company of $125,000. The note is due on May 3, 2022 and bears interest on the unpaid principal balance at a rate of 12% per annum. Stringent pre-payment terms apply (from 15% to 40%, dependent upon the timeframe of repayment during the note's term) and any part of the note which is not paid when due shall bear interest at the rate of 22% per annum from the due date until paid. The Note may be converted by the Lender at any time after 180 days of the date of issuance into shares of Company's common stock at a conversion price equal to 61% of the lowest trading price during the 15-trading day period prior to the conversion date. As the stock price at the issuance date was lesser than the effective conversion price, it was determined that no beneficial conversion feature exists. As the note is not convertible until 180 days following issuance, no derivative liability was recognized as of September 30, 2021. On November 5, 2021, the Company repaid the $128,000 note as well as $61,952 of interest and prepayment penalties.

 

 

NOTE 7. DERIVATIVE LIABILITIES

 

The embedded conversion option of (1) the convertible notes payable described in Note 5; (2) warrants; contain conversion features that qualify for embedded derivative classification. The fair value of the liabilities will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on derivative financial instruments.

 

Upon the issuance of the convertible notes payable described in Note 6, the Company concluded that it only has sufficient shares to satisfy the conversion of some but not all of the outstanding convertible notes, warrants and options. The Company elected to reclassify contracts from equity with the earliest inception date first. As a result, none of the Company's previously outstanding convertible instruments qualified for derivative reclassification, however, any convertible securities issued after the election, including the warrants described in Note 10, qualified for derivative classification. The Company reassesses the classification of the instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification.

 

The table below sets forth a summary of changes in the fair value of the Company's Level 3 financial liabilities.

 

    September 30,
2021
  December 31,
2020
Balance at the beginning of period   $ 7,102,801     $ 10,517,873  
Original discount limited to proceeds of notes     -       166,000  
Settlement of derivative instruments     (3,792,104 )     (16,824,669 )
Change in fair value of embedded conversion option     (1,749,277 )     13,243,597  
Balance at the end of the period   $ 1,561,420     $ 7,102,801  

 

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option and warrant liabilities as their fair values were determined by using the Binomial Model based on various assumptions. 

 

Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the assumptions used in the calculations:

 

    Expected Volatility     Risk-free Interest Rate     Expected Dividend Yield     Expected Life (in years)  
At September 30, 2021     113 - 249 %     0.09-0.76 %     0 %     1.00-3.91  

 

The Company uses Level 3 inputs for its valuation methodology for the preferred series A stock liability as their fair values were determined by using the Binomial Model based on various assumptions. 

 

 

  18  

 

NOTE 8. STOCKHOLDERS' DEFICIT

 

Preferred Stock

Effective March 23, 2018, the Company amended the articles of incorporation and authorized 10,000,000 shares of preferred stock with a par value of $0.001 per share. The preferred stock may be issued from time to time by the Board of Directors as shares of one or more classes or series, as summarized below.

 

Series A Preferred Shares

Effective March 23, 2018, the Company amended the articles of incorporation and authorized 10,000,000 shares of preferred stock with a par value of $0.001 per share, of which 1,000,000 shares were designated as Series A Convertible Preferred Stock as of December 31, 2019. The preferred stock may be issued from time to time by the Board of Directors as shares of one or more classes or series.

 

On December 1, 2018, the Company's Board of Directors authorized an offering for 1,000,000 Preferred Series "A" stock at $0.10 per share and with 100% regular or cashless exercise at $0.10 per share of common stock warrant coverage. At December 31, 2018, the Company received $60,000 of subscriptions for the issuance of 600,000 shares of Preferred Series "A" stock to three accredited investors who are related parties. The Company was unable to issue the subscriber the preferred shares until the Company filed a Certificate of Designation and the Preferred Series "A" stock has been duly validly authorized. Resulting in a preferred stock liability related to the Company's commitment to issue shares of Series A stock upon the designation.

 

On April 12, 2019, the Company filed a Certificate of Designation with the Nevada Secretary of State designating 1,000,000 shares of its authorized preferred stock as Series A Convertible Preferred Stock. The principal terms of the Series A Preferred Shares are as follows:

Issue Price

The stated price for the Series A Preferred shall be $0.10 per share.

Redemption

This Company may at any time following the first anniversary date of issuance (the "Redemption Date"), at the option of the Board of Directors, redeem in whole or in part the Shares by paying in cash in exchange for the Shares to be redeemed a price equal to the Original Series A Issue Price ($0.10) (the "Redemption Price"). Any redemption affected pursuant to this provision shall be made on a pro rata basis among the holders of the Shares in proportion to the number of the shares then held by them.

Dividends

None.

Preference of Liquidation

In the event of any liquidation, dissolution or winding up of the Company, the holders of Shares shall be entitled to receive, prior and in preference to any distribution of any of the assets of this Company, to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the sum of (i) $0.10 for each outstanding Share (the "Original Series A Issue Price") and (ii) an amount equal to 6% of the Original Series A Issue Price for each 12 months that has passed since the date of issuance of any Shares (such amount being referred to herein as the "Premium").

For purposes of this provision, a liquidation, dissolution or winding up of this Company shall be deemed to be occasioned by, or to include, (A) the acquisition of the Company by another entity by means of any transaction or series of related transactions (including, without limitation, any reorganization, merger or consolidation but, excluding any merger effected exclusively for the purpose of changing the domicile of the Company); or (B) a sale of all or substantially all of the assets of the Company; unless the Company's stockholders of record as constituted immediately prior to such acquisition or sale will, immediately after such acquisition or sale (by virtue of securities issued as consideration for the Company's acquisition or sale or otherwise), hold at least 50% of the voting power of the surviving or acquiring entity.

If upon the occurrence of such liquidation, dissolution or winding up event, the assets and funds thus distributed among the holders of the Shares shall be insufficient to permit the payment to such holders of the full aforesaid preferential amounts, then, subject to the rights of series of preferred stock that may from time to time come into existence, the entire assets and funds of the Company legally available for distribution shall be distributed ratably among the holders of the Shares in proportion to the preferential amount each such holder is otherwise entitled to receive.

In any of such liquidation, dissolution or winding up event, if the consideration received by the Company is other than cash, its value will be deemed its fair market value. Any securities shall be valued as follows:

  19  

 

  A. Securities not subject to investment letter or other similar restrictions on free marketability (covered by (B) below):

 

  1) If traded on a securities exchange (NASDAQ, AMEX, NYSE, etc.), the value shall be deemed to be the average of the closing prices of the securities on such exchange over the thirty-day period ending three (3) days prior to the closing;

 

  2) If traded on a quotation system, such as the OTC:QX, OTC:QB or OTC Pink Sheets, the value shall be deemed to be the average of the closing bid or sale prices (whichever is applicable) over the thirty-day period ending three (3) days prior to the closing; and

 

  3) If there is no active public market, the value shall be the fair market value thereof, as mutually determined by the Company and the holders of at least a majority of the voting power of all then outstanding shares of Preferred Stock.

 

  B. The method of valuation of securities subject to investment letter or other restrictions on free marketability (other than restrictions arising solely by virtue of a stockholder's status as an affiliate or former affiliate) shall be to make an appropriate discount from the market value determined as above in (A) (1), (2) or (3) to reflect the approximate fair market value thereof, as mutually determined by the Company and the holders of at least a majority of the voting power of all then outstanding shares of such Preferred Stock:

Voting

The holder of each Share shall not have any voting rights, except in the case of voting on a change in the preferences of Shares.

Conversion

Each Share shall be convertible into shares of the Company's Common Stock at a price per share of $0.10 (1 Share converts into 1 share of Common Stock), at the option of the holder thereof, at any time following the date of issuance of such Share and on or prior to the fifth day prior to the Redemption Date, if any, as may have been fixed in any Redemption Notice with respect to the Shares, at the office of this Company or any transfer agent for such stock. Each Share shall automatically be converted into shares of Common Stock on the first day of the thirty-sixth (36th) month following the original issue date of the shares at the Conversion Price per share.

 

The Company was unable to issue the subscribers the preferred shares until the Company filed a Certificate of Designation and the Preferred Series "A" stock had been duly validly authorized. As the Company had not filed the Certificate of Designation and as the Company could not issue the preferred shares to settle the proceeds received, it was determined the subscriptions were settleable in cash. As a result, the Company classified the subscriptions received as a liability in accordance with ASC 480 Distinguishing Liabilities from Equity. The filing of the Certificate of Designation and issuance of the preferred shares resulted in the reclassification of the Series A Preferred Shares from a liability to temporary equity or "mezzanine" because the preferred shares include the liquidation preferences described above. The fair value of the preferred series A stock on April 12, 2019 was $60,398 and was valued by using the Binomial Model based on various assumptions and was reclassified from a liability to mezzanine equity.

As of September 30, 2021, and December 31, 2020, there were 500,000 shares of Series A Convertible Preferred Stock issued and outstanding, respectively.

Series B Preferred Shares

Effective August 13, 2019, the Company filed a Certificate of Designation with the Nevada Secretary of State thereby designating 1,000,000 shares of its authorized preferred stock as Series B -Preferred Stock. The principal terms of the Series B Preferred Shares are as follows:

Voting Rights

Holders of the Series B Preferred Stock shall be entitled to cast five hundred (500) votes for each share held of the Series B Preferred Stock on all matters presented to the stockholders of the Corporation for stockholder vote which shall vote along with holders of the Corporation's Common Stock on such matters.

  20  

 

Redemption Rights

The Series B Preferred Stock shall be redeemed by the Corporation upon the successful receipt by the Corporation of at least $1,000,000 in equity capital following the issuance of the Series B Preferred Stock. To date the Company has received $500,500 of equity capital, and upon the receipt of an additional $499,500 in equity capital the redemption right will be triggered.

Conversion Rights

The Series B Preferred Stock is not convertible into shares of Common Stock of the Corporation.

Protective Provisions

So long as any shares of Series B Preferred Stock are outstanding, this Corporation shall not without first obtaining the approval (by vote or written consent, as provided by law) of the Holders of the Series B Preferred Stock which is entitled, other than solely by law, to vote with respect to the matter, and which Preferred Stock represents at least a majority of the voting power of the then outstanding shares of such Series B Preferred Stock:

  a) sell, convey, or otherwise dispose of or encumber all or substantially all of its property or business or merge into or consolidate with any other corporation (other than a wholly owned subsidiary corporation) or effect any transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Corporation is disposed of; 

 

  b) alter or change the rights, preferences or privileges of the shares of Series B Preferred Stock so as to affect adversely the shares;

 

  c) increase or decrease (other than by redemption or conversion) the total number of authorized shares of preferred stock;

 

  d) authorize or issue, or obligate itself to issue, any other equity security, including any other security convertible into or exercisable for any equity security (i) having a preference over, or being on a parity with, the Series B Preferred Stock with respect to dividends or upon liquidation, or (ii) having rights similar to any of the rights of the Series B Preferred Stock; or

 

  e) amend the Corporation's Articles of Incorporation or bylaws.

Dividends

None.

Preference of Liquidation

None

Upon designation, the Company issued 500,000 shares of the Series B preferred stock to each of its current CEO/Chairman and COO/Director (1,000,000 shares in total) pursuant to their employment agreements. As the Series B Preferred Shares represent share-based payments that are not classified as liabilities but that could require the employer to redeem the equity instruments for cash or other assets, the Company classified the initial redemption amount of the shares of $158,247 as temporary equity or "mezzanine".

 

As of September 30, 2021, and December 31, 2020, there were 1,000,000 shares of Series B Preferred Stock issued and outstanding, respectively.

 

Series C Preferred Shares

Pursuant to the September 18, 2019 majority consent of stockholders in lieu of an annual meeting (including the consent of the Series A Convertible Preferred Stockholders), the Registrant filed a Certificate of Designation with the Nevada Secretary of State designating 5,500,000 shares of its authorized preferred stock as Series C Convertible Preferred Stock. The Registrant is awaiting the file stamped Certificate of Designation from the Nevada Secretary of State. The rights and preferences of such preferred stock are as follows:

 

  21  

 

The number of shares constituting the Series C Convertible Preferred Stock shall be 5,500,000. Such number of shares may be increased or decreased by resolution of the Board of Directors, provided that no decrease shall reduce the number of shares of Series C Convertible Preferred Stock to a number less than the number of shares then outstanding plus the number of shares reserved for issuance upon the exercise of outstanding options, rights or warrants or upon the conversion of any outstanding securities issued by the Company convertible into Series C Convertible Preferred Stock.

Conversion Rights

Each Share shall be convertible into shares of the Company's Common Stock at a price per share of $0.01 (1 Share converts into 100 shares of Common Stock) (the "Conversion Price"), at the option of the holder thereof, at any time following the date of issuance of such Share and on or prior to the fifth (5th) day prior to the redemption Date, if any, as may have been fixed in any redemption notice with respect to the Shares, at the office of this Company or any transfer agent for such stock.

Voting Rights

The holder of each Share shall not have any voting rights, except in the case of voting on a change in the preferences of Shares.

Protective Provisions

So long as any Shares are outstanding, this Company shall not without first obtaining the approval (by vote or written consent, as provided by law) of the holders of Shares which is entitled, other than solely by law, to vote with respect to the matter, and which Shares represents at least a majority of the voting power of the then outstanding Shares:

  a) sell, convey, or otherwise dispose of or encumber all or substantially all of its property or business or merge into or consolidate with any other corporation (other than a wholly owned subsidiary corporation) or effect any transaction or series of related transactions in which more than fifty percent (50%) of the voting power of the Company is disposed of;

  b) alter or change the rights, preferences or privileges of the Shares so as to affect adversely the Shares;

  c) increase or decrease (other than by redemption or conversion) the total number of authorized shares of preferred stock;

  d) authorize or issue, or obligate itself to issue, any other equity security, including any other security convertible into or exercisable for any equity security (i) having a preference over, or being on a parity with, the Shares with respect to liquidation, or (ii) having rights similar to any of the rights of the Preferred Stock; or

  e) amend the Company's Articles of Incorporation or bylaws.

Other Rights

There are no other rights, privileges or preferences attendant or relating to in any way the Shares, including by way of illustration but not limitation, those concerning dividend, ranking, other conversion, other redemption, participation or anti-dilution rights or preferences.

As conversion of the Series C Preferred Shares is not within the control of the Company, and it is not certain that the Company could satisfy its obligation to deliver shares upon conversion, the Series C Preferred Shares were classified in temporary equity or "mezzanine".

At December 31, 2020, there were 40,000 Series C Preferred Shares issued and outstanding, valued at $1 per share or $40,000.

On February 15, 2021, 40,000 shares of preferred series C stock was converted into common stock (1 share converts into 100 shares of common stock), resulting in the issuance of 4,000,000 shares of common stock. At September 30, 2021, no Series C Preferred Shares were outstanding.

 

  22  

 

Common Stock

 

Effective March 23, 2018, the Company amended the Articles of Incorporation and increased the authorized shares of common stock with a par value of $0.001 per share from 100,000,000 to 300,000,000 shares. Effective October 4, 2019, the Company amended the Articles of Incorporation and increased the authorized shares of common stock with a par value of $0.001 per share from 300,000,000 to 1,000,000,000 shares. The number of shares outstanding of the registrant's common stock as of September 30, 2021 and December 31, 2020 was 780,126,229 and 722,487,846, respectively.

 

On January 4, 2021, the Company issued 25,000,000 common shares to settle a convertible note described in Note 6(p), with a remaining balance of $40,000.

 

On February 15, 2021, 40,000 shares of preferred series C stock was converted into common stock (1 share converts into 100 shares of common stock), resulting in the issuance of 4,000,000 shares of common stock.

 

On February 16, 2021, the Company issued 1,803,279 shares of common stock to settle $247,270 from a $275,000 note payable dated June 20, 2018, which has a balance of $331,304, including interest, to the current Chairman and CEO of the Company.

 

On February 16, 2021, the Company issued 2,663,299 shares of common stock to settle a June 20, 2018 note payable of $380,000 and accrued interest of $26,153 owed to the current COO and Director of the Company.

 

On March 1, 2021, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant will provide advisory services through May 31, 2021 in consideration of 2,500,000 shares of common stock. The fair value of the common stock was $62,750 which has been recognized in consulting expense during the six months ended June 30, 2021.

 

On May 7, 2021, the Company issued 1,921,875 common shares pursuant to a cashless exercise of warrants as described in Note 6(l).

 

On May 27, 2021, the Company issued 1,000,000 common shares pursuant to an employment agreement dated May 5, 2021 with an officer of the Company. The fair value of the common stock was $18,990.

 

On June 2, 2021, the Company issued 3,750,000 common shares for cash proceeds of $75,000.

 

On June 30, 2021, the Company issued 5,000,000 common shares for cash proceeds of $100,000.

 

On September 1, 2021, the Company issued 8,000,000 common shares and paid $21,000 to settle the remaining outstanding principal on a convertible note payable of $88,795 and accrued interest of $26,153 resulting in a gain on settlement of debt of $20,364.

 

On September 10, 2021, the Company issued 2,000,000 common shares pursuant to a general release agreement dated July 23, 2021 with a former employee of the Company. The fair value of the common stock was $28,400.

 

 

NOTE 9. STOCK OPTIONS

 

Below is a table summarizing the options issued and outstanding as of September 30, 2021:

 

    Number of
options
  Weighted average exercise price
$
  Balance, December 31, 2020       200,000       2.00  
  Granted                  
  Expired                  
  Settled                  
  Balance, September 30, 2021       200,000       2.00  

 

As at September 30, 2021, the following share stock options were outstanding:

 

Date   Number   Number   Exercise   Weighted Average Remaining Contractual   Expiration   Proceeds to Company if
Issued   Outstanding   Exercisable   Price $   Life (Years)   Date   Exercised
  01/26/2017       200,000       200,000       2.00       0.32       01/26/2022       400,000  
          200,000       200,000                             $ 400,000  

 

The weighted average exercise prices are $2.00 for the options outstanding and exercisable, respectively. The intrinsic value of stock options outstanding at September 30, 2021 was $nil.

 

  23  

 

 

NOTE 10. WARRANTS

 

The Company concluded that it only has sufficient shares to satisfy the conversion of some but not all of the outstanding convertible instruments. The initial fair value of the warrants issued during the period was calculated using the Binomial Model as described in Note 6.

 

The following table summarizes the continuity of share purchase warrants:

 

    Number of
warrants
  Weighted average exercise price
$
  Balance, December 31, 2020       260,500,000       0.00283  
  Settled                  
  Granted                  
  Exercised       (142,857,143 )     0.00035  
  Balance, September 30, 2021       117,642,857       0.00584  

 

As at September 30, 2021, the following share purchase warrants were outstanding:

 

Date   Number   Number   Exercise   Weighted Average Remaining Contractual   Expiration   Proceeds to Company if
Issued   Outstanding   Exercisable   Price $   Life (Years)   Date   Exercised
  12/3/2018       500,000       500,000       0.10       2.18       12/3/2023       50,000  
  3/31/2019       107,142,857     107,142,857 *     0.00035 *     2.45       03/13/2024       37,500  
  8/26/2020       10,000,000     10,000,000 *     0.06 *     3.91       8/26/2025       600,000  
          117,642,857       117,642,857                             $ 687,500  

  

*The number of warrants outstanding and exercisable is variable based on adjustments to the exercise price of the warrant due to dilutive issuances.

 

The intrinsic value of warrants outstanding at September 30, 2021 was $1,237,500.

 

 

NOTE 11. RELATED PARTY TRANSACTIONS

 

The Company has agreements with related parties for consulting services, accrued rent, accrued interest, notes payable and stock options. See Notes to Financial Statements numbers 6, 8, 9 and 11 for more details.

 

 

NOTE 12. COMMITMENTS AND CONTINGENCIES

 

Consulting Agreements - 

 

On March 1, 2021, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant will provide consulting services to the Company in various marketing and management matters for a period of three months. In consideration for the services performed by the consultant, the Company agreed to compensate the consultant $5,000 per month.

 

The Company also uses the professional services of securities attorneys, a US EPA specialist, professional accountants and other public-company specialists.

 

Employment Agreements -

 

On May 5, 2021, the Company entered into an employment agreement with a recently appointed officer, for an initial term of three years. The terms of the contract call for an annual salary of $70,000 and the issuance of 1,000,000 shares of common stock. The fair value of the common stock was $18,990. On July 16, 2021, the officer resigned.

 

Other Obligations and Commitments -

 

The Company has a commitment to acquire inventory for a total cost of $61,150, of which $30,575 was paid prior to September 30, 2021.

 

Other than the above, there are no new obligation or commitments during the period ending September 30, 2021.

 

 

NOTE 13. SUBSEQUENT EVENTS

 

a) On October 11, 2011, the Company issued 15,000,000 common shares upon the conversion of the remaining $15,000 of the convertible note payable, leaving a note balance of $0. Refer to Note 6(w).

 

b) Effective October 14, 2021, the Company terminated a building lease with an original expiry date of March 31, 2023. Refer to Note 5.

 

3) On November 5, 2021, the Company repaid a $128,000 convertible note as well as $61,952 of interest and prepayment penalties. Refer to Note 6(hh).

 

  24  

 

 

FORWARD-LOOKING STATEMENTS

 

This document contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements or belief; and any statements of assumptions underlying any of the foregoing.

 

Forward-looking statements may include the words "may," "could," "estimate," "intend," "continue," "believe," "expect" or "anticipate" or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the dates on which they are made. We do not undertake to update forward-looking statements to reflect the impact of circumstances or events that arise after the dates they are made. You should, however, consult further disclosures we make in this Quarterly Report on Form 10-Q, future Quarterly Reports on Form 10-Q, our Annual Report on Form 10-K and Current Reports on Form 8-K.

 

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. The factors impacting these risks and uncertainties include, but are not limited to:

 

•  our ability to efficiently manage and repay our debt obligations;
•  our inability to raise additional financing for working capital;
•  our ability to generate sufficient revenue in our targeted markets to support operations;
•  significant dilution resulting from our financing activities;
•  actions and initiatives taken by both current and potential competitors;
•  supply chain disruptions for components used in our products;
•  manufacturers inability to deliver components or products on time;
•  our ability to diversify our operations;
•  the fact that our accounting policies and methods are fundamental to how we report our financial condition and results of operations, and they may require management to make estimates about matters that are inherently uncertain;
•  adverse state or federal legislation or regulation that increases the costs of compliance, or adverse findings by a regulator with respect to existing operations;
•  changes in U.S. GAAP or in the legal, regulatory and legislative environments in the markets in which we operate;
•  deterioration in general or global economic, market and political conditions;
•  inability to efficiently manage our operations;
•  inability to achieve future operating results;
•  the unavailability of funds for capital expenditures;
•  our ability to recruit, hire and retain key employees;
•  the global impact of COVID-19 on the United States economy and out operations;
•  the inability of management to effectively implement our strategies and business plans; and
•  the other risks and uncertainties detailed in this report. 

 

In this form 10-Q references to "PCT LTD", "the Company", "we," "us," "our" and similar terms refer to PCT LTD and its wholly owned operating subsidiary, Paradigm Convergence Technologies Corporation ("Paradigm").

 

COVID-19

 

The current and potential effects of coronavirus may impact our business, results of operations and financial condition.

 

Actual or threatened epidemics, pandemics, outbreaks, or other public health crises could materially and adversely impact or disrupt our operations, adversely affect the local economies where we operate and negatively impact our customers' spending in the impacted regions or depending upon the severity, globally, which could materially and adversely impact our business, results of operations and financial condition. For example, since December 2019, a strain of novel coronavirus (causing "COVD-19") surfaced in China and has spread into the United States, Europe and most other countries of the world, resulting in certain supply chain disruptions, volatilities in the stock market, lower oil and other commodity prices due to diminished demand, massive unemployment, and lockdown on international travels, all of which has had an adverse impact on the global economy. There is significant uncertainty around the breadth and duration of the business disruptions related to COVID-19, as well as its impact on the U.S. economy. Moreover, an epidemic, pandemic, outbreak or other public health crisis, such as COVID-19, could adversely affect our ability to adequately staff and manage our business. The extent to which COVID-19 impacts our business, results of operations and financial condition will depend on future developments, which are highly uncertain, rapidly changing and cannot be predicted, including new information that may emerge concerning the severity of COVID-19 and the actions taken to contain it or treat its impact.

 

 

  25  

 

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Executive Overview

 

On August 31, 2016, PCT LTD entered into a Securities Exchange Agreement (the "Exchange Agreement") with Paradigm Convergence Technologies Corporation, a Nevada corporation ("Paradigm"). Pursuant to the terms of the Exchange Agreement, Paradigm became the wholly-owned subsidiary of PCT LTD after the exchange transaction. PCT LTD is a holding company, which through Paradigm is engaged in the business of marketing new products and technologies through licensing and joint ventures.

 

PCT LTD had not recorded revenues for the two fiscal years prior to its acquisition of Paradigm and was dependent upon financing to continue basic operations. Paradigm has recorded revenue since it initiated operations in 2012; however, those revenues have not been sufficient to finance operations. The Company recorded a net income of $3,207,572 for the nine-months ended September 30, 2021 and accumulated losses of $27,380,040 from inception through September 30, 2021.

 

PCT LTD remains dependent upon additional financing to continue operations. The Company intends to raise additional financing through private placements of its common stock and note payable issuances. We expect that we would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The purchasers and manner of issuance will be determined according to our financial needs, as discussed below, and the available exemptions to the registration requirements of the Securities Act of 1933. We also note that if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common stock.

The expected costs for the next twelve months include:

 

  continuation of commercial launch of non-toxic sanitizing, disinfecting and sterilizing products and technologies with a strong emphasis on health care facilities, including hospitals, nursing homes, assisted living facilities, clinics and medical, dental and veterinarian offices;

 

  continued research and development on product generation units including those designed for on-site deployment at customers' facilities;

 

  accelerated research and development and initial commercialization on applications of the products in the agricultural sector, most specifically with respect to abatement of a specific crop disease crisis caused by a bacterium in the U.S. and elsewhere;

 

  acquiring available complementary technology rights;

 

  payment of short-term debt;

 

  hiring of additional personnel in 2021; and

 

  general and administrative operating costs.

 

Management projects these costs to total approximately $2,400,000. To minimize these costs, the Company intends to maintain its practice of controlling operating overheads with efficient facilities commitments, generally below market salaries and consulting fees, and rigorous prioritization of expenditure requirements. Based on its understanding of the commercial readiness of its products and technologies, the capabilities of its personnel (current and being hired), established business relationships and the general market conditions, management believes that the Company expects to be covering its fixed operating expenses ("burn rate") by the end of the third quarter of 2022.

 

 

  26  

 

Liquidity and Capital Resources

 

A critical component of our operating plan impacting our continued existence is the ability to obtain additional capital through additional equity and/or debt financing. We do not anticipate generating sufficient positive internal operating cash flow until such time as we can deliver our products to market and generate substantial revenues, which may take the next full year to fully realize, if ever. In the event we cannot obtain the necessary capital to pursue our strategic plan, we may have to significantly curtail our operations. This would materially impact our ability to continue operations.

 

SUMMARY OF BALANCE SHEET   September 30,
2021
  December 31,
2020
Cash and cash equivalents   $ 239,327     $ 115,196  
Total current assets     601,778       747,756  
Total assets     4,186,339       4,634,610  
Total liabilities     6,217,722       11,038,156  
Accumulated deficit     (27,380,040 )     (30,587,612 )
Total stockholders' deficit   $ (2,250,028 )   $ (6,662,191 )

 

For the nine months ended September 30, 2021, the Company recorded net income of $3,207,572 and at September 30, 2021 had a working capital deficit of $5,563,299. While we have recently recorded an increase in the amount of revenues from operations, since inception and we had not established an ongoing source of revenue sufficient to cover our operating costs. During the nine-months ended September 30, 2021 and 2020 we primarily relied upon advances and loans from stockholders and third parties to fund our operations. The Company has relied on raising debt and equity capital in order to fund its ongoing day-to-day operations and its corporate overhead. We had $239,327 in cash at September 30, 2021, compared to $115,196 in cash at December 31, 2020. We had total liabilities of $6,217,722 at September 30, 2021 compared to $11,038,156 at December 31, 2020.

 

Our current cash flow is not sufficient to meet our monthly expenses of approximately $200,000 and to fund future research and development adequately. We intend to rely on additional debt financing, loans from existing stockholders and private placements of common stock for additional funding in addition to the increasing our recognized revenue from the leasing and/or sale of products; however, there is no assurance that additional funding will be available. We do not have material commitments for future capital expenditures. However, we cannot assure you that we will be able to obtain short-term financing, or that sources of such financing, if any, will continue to be available, and if available, that they will be on favorable terms.

 

During the next 12 months we anticipate incurring additional costs related to the filing of Exchange Act reports. We believe we will be able to meet these costs through funds provided by management, significant stockholders and/or third parties. We may also rely on the issuance of our common stock in lieu of cash to convert debt or pay for expenses.

  

Commitments and Obligations

 

At September 30, 2021 the Company recorded notes payable totaling approximately $2,262,113 (related, non-related and convertible, net of debt discount) compared to notes payable totaling $2,781,597 (related, non-related and convertible, net of debt discount) at December 31, 2020. These notes payable represent cash advances received and expenses paid from third parties and related parties. All of the notes payable carry effective interest from 0% to 211% and are due ranging from on demand to May 3, 2022.

 

The Company headquarters and operations is located in Little River, South Carolina. The Company re-negotiated an annual lease on the Little River, SC facility for $7,500 per month, retroactive to July 1, 2020, which is renewable for an additional four years (with a 2% increase annually). Effective July 1, 2021 through June 30, 2022, the monthly lease payment is $7,650. The Company added a three-year lease for 9,600 sf. of warehouse space in Fort Wayne, Indiana on November 1, 2020, for $4,500/month. Effective March 15, 2021, the Company entered into a 2-year lease for additional office space in Little River, SC, for $2,750 per month, which was terminated effective October 14, 2021.

 

  27  

 

Results of Operations

 

Three Months Ended September 30, 2021

 

SUMMARY OF OPERATIONS   Three-month period ended
September 30,
    (Unaudited)
    2021   2020
Revenues   $ 366,730     $ 784,088  
Total operating expenses     1,229,810       776,114  
Total other income (expense)     716,893       (3,813,932 )
Net income (loss)     (146,187     (3,805,958 )
Net income (loss) attributable to common stockholders'     (146,187     (3,805,958 )
Basic income (loss) per share     (0.00     (0.01 )
Diluted income (loss) per share   $ (0.00 )   $ (0.01 )

 

Revenues decreased to $366,730, for the three-months ended September 30, 2021 (the "2021 third quarter") compared to $784,088 for the three-months ended September 30, 2021 (the "2020 third quarter"). The revenue decrease for the period was due to the decreased volume of fluids sold, as a result of the decreased need for an effective US EPA-registered disinfectant as the country started to come out of the COVID-19 pandemic.

 

Total operating expenses increased to $1,229,810 during the 2021 third quarter compared to $776,114 during the 2020 third quarter. The increase during the third quarter of 2021 was primarily due to an increase in general and administrative expenses.

 

General and administrative expenses increased to $1,031,072 for the 2021 third quarter compared to $614,667 during the 2020 third quarter. The increase during the third quarter of 2021 was primarily due to stock-based compensation for consulting services and a provision for bad debts.

 

Depreciation and amortization expenses increased slightly to $98,364 during the 2021 third quarter compared to $90,999 during the 2020 third quarter.

 

Total other income was $716,893 for the 2021 third quarter compared to other expense of $3,813,932 during the 2020 third quarter. The overall change was a primarily due to a gain on settlement of debt of $361,357 during the 2021 third quarter versus a loss on settlement of debt of $3,670,393 during the third quarter of 2020.

 

As a result of the changes described above, net loss was $146,187 during the 2021 third quarter compared to a net loss of $3,805,958 during the 2020 third quarter.

 

Nine Months Ended September 30, 2021

 

SUMMARY OF OPERATIONS   Nine months period ended
September 30,
    (Unaudited)
    2021   2020
Revenues   $ 1,231,392     $ 1,937,442  
Total operating expense   $ 3,133,929     $ 2,651,016  
Total other income (expense)   $ 5,110,109     $ (6,354,949 )
Net income (loss)   $ 3,207,572     $ (7,068,523 )
Preferred series C stock deemed dividends     -       (270,000 )
Net income (loss) attributable to common stockholders'     3,207,572       (7,338,523 )
Basic income (loss) per share     0.00       (0.01 )
Diluted income (loss) per share   $ (0.00 )   $ (0.01 )

 

Revenues decreased to $1,231,392 for the nine months ended September 30, 2021 compared to $1,937,442 for the nine months ended September 30, 2021. The revenue decrease for the period was primarily due to the decreased volume of fluids sold as a result of the decreased need for an effective US EPA-registered disinfectant as the country came out of the COVID-19 pandemic. Accordingly, product sales decreased to $204,138 during the nine-months ended September 30, 2021 compared to $1,233,058 during the nine-months ended September 30, 2020. However, revenue for equipment leases increased to $802,132 during the nine-months ended September 30, 2021 compared to $501,384 during the nine-months ended September 30, 2020.

 

  28  

 

Total operating expenses increased to $3,133,929 during the nine months ended September 30, 2021 compared to $2,651,016 during the nine months ended September 30, 2020. The increase during the period was primarily due to an increase in general and administrative expenses of $827,644 partially offset by a decrease in cost of product, licensing, and equipment leases of $393,646.

 

General and administrative expenses increased to $2,583,139 for the nine months ended September 30, 2021 compared to $1,755,495 during the nine months ended September 30, 2020. General and administrative increased due to stock-based compensation for consulting services, salaries and wages, bad debt provision and professional and accounting fees.

 

Depreciation and amortization expenses increased to $295,092 during the nine months ended September 30, 2021 compared to $255,368 during the nine months ended September 30, 2020.

 

Total other income was $5,110,109 for the nine months ended September 30, 2021 compared to other expense of $6,354,949 during the nine months ended September 30, 2020. The overall change was a primarily due to a gain on change in fair value of derivative liability of $1,749,277 and a gain on settlement of debt of $3,689,055 during the nine months ended September 30, 2021 versus a loss on change in fair value of derivative liability of $15,253,543 and a gain settlement of debt of $9,993,528 during the nine months ended September 30, 2020.

 

As a result of the changes described above, net income was $3,207,572 during the nine months ended September 30, 2021 compared to a net loss of $7,068,523 during the nine months ended September 30, 2020.

 

Off-Balance Sheet Arrangements

 

We have not entered into any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.

 

Critical Accounting Policies

 

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

 

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management's estimates are based on historical experience, on information from third party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable to smaller reporting companies.

 

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) or 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the periods specified in the rules and forms of the SEC. This information is accumulated to allow our management to make timely decisions regarding required disclosure. Gary Grieco, our Chief Executive Officer, who serves as our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) and Rule 15d-15(e) of the Exchange Act) as of the end of the period covered by this report. The disclosure controls and procedures ensure that all information required to be disclosed by us in the reports that we file or submit under the Exchange Act is: (i) recorded, processed, summarized and reported, within the time periods specified in the SEC's rule and forms; and (ii) accumulated and communicated to our principal executive officer as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive officer concluded that as of September 30, 2021, our disclosure controls and procedures were not effective.  

 

Notwithstanding this finding of ineffective disclosure controls and procedures, we concluded that the consolidated financial statements included in this Form 10-Q present fairly, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States.

 

Changes in Internal Control Over Financial Reporting

 

During the quarter ended September 30, 2021, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934).

 

 

  29  

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

Auctus Fund Settlement

 

In March of 2019, we entered into a Securities Purchase Agreement with Auctus Fund, LLC (“Auctus”), whereby we borrowed $75,000 from Auctus under the terms of a convertible promissory note and included the issuance to 187,500 warrants to Auctus. Adjustment provisions in the Securities Purchase Agreement and the note required PCTL to adjust the number of warrants and exercise price based upon future financings. 

 

In late 2019, we defaulted on the Auctus note, which triggered a number of default provisions of the note. We disputed the amounts claimed to be owed to Auctus, the number of shares of common stock to be reserved for conversion of the note and the number and exercise price of the warrants held by Auctus. Negotiations of these disputes lasted for several months.

 

In October of 2020, we entered into a Conditional Settlement Agreement with Auctus to settle all disputes and claims between the parties. A material dispute between the parties was the warrants, which according the Auctus had ballooned to 107,142,857 shares at an exercise price of $0.00035. Pursuant to the settlement agreement, Auctus agreed to settle such disputes and claims based upon the payment of $145,000 in cash and the issuance of 8,000,000 shares of common stock.

 

On September 1, 2021, we issued 8,000,000 common shares and paid the remaining cash balance to Auctus under the terms of the settlement. We fully complied with all payments required under the settlement agreement and issued the shares of common stock to Auctus, which triggered the mutual release of all disputes and claims between us and Auctus. Despite our compliance with the terms of the settlement agreement, Auctus has refused to execute the mutual release required by the settlement agreement and acknowledge the cancellation of the warrants as part of the settlement.

 

As of the date of this filing, we are exploring our remedies against Auctus, which may include filing legal action for breach of the settlement agreement and seeking a declarotory judgment as to the cancellation of the warrants. We are also continuing to seek cooperation with Auctus in settlement of this ongoing dispute. 

 

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and, as such, are not required to provide the information under this Item. However, we detailed significant business risks in Item 1A to our Form 10-K/A for the year ended December 31, 2020.

 

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

On January 4, 2021, the Company issued 25,000,000 common shares to settle a convertible note described in Note 6(bb), with a remaining balance of $40,000.

 

On February 15, 2021, 40,000 shares of preferred series C stock was converted into common stock (1 share converts into 100 shares of common stock), resulting in the issuance of 4,000,000 shares of common stock.

 

On February 16, 2021, the Company issued 1,803,279 shares of common stock to settle $247,270 from a $275,000 note payable dated June 20, 2018, which has a balance of $331,304, including interest, to the current Chairman and CEO of the Company. The Company also agreed to issue a new note for the remaining balance owed to the Chairman and CEO of $84,034, dated February 16, 2021. The note will bear interest at 5% per annum and is due on June 30, 2021.

 

On February 16, 2021, the Company issued 2,663,299 shares of common stock to settle a June 20, 2018 note payable of $380,000 and accrued interest of $26,153 owed to the current COO and Director of the Company.

 

On March 1, 2021, the Company released an additional vested 375,000 shares of common stock to its current COO and Director, as per the Company employment agreement with the executive. 

 

On March 1, 2021, the Company entered into a consulting agreement. Pursuant to the agreement, the consultant will provide advisory services for a period of three months in consideration of $5,000 per month and an option to purchase 2,500,000 shares of common stock at $0.0001 for one year, exercisable on issuance.

 

On April 5, 2021, the Company entered into a convertible promissory note with a non-related party for $43,000. The Note is due on April 5, 2022 and bears interest on the unpaid principal balance at the rate of 12% per annum. The Note may be converted by the lender at any time before 6-months of the date of issuance into shares of Company's common stock at the conversion price equal to 61% multiplied by the Market Price.

 

On April 14, 2021, the Company entered into a convertible promissory note with a non-related party for $200,000. The Note is due on April 14, 2022 and bears interest on the unpaid principal balance at the rate of 5% per annum. The Note may not be converted by the lender before 6 months of the issuance date into shares of Company's common stock at a conversion price equal to $0.10.

 

  30  

 

On May 3, 2021, the Company entered into a convertible promissory note with a non-related party for $128,000. The Note is due on May 3, 2022 and bears interest on the unpaid principal balance at the rate of 12% per annum. The Note may be converted by the lender at any time before 6-months of the date of issuance into shares of Company's common stock at the conversion price equal to 61% multiplied by the Market Price.

 

On May 5, 2021, the Company entered into an employment agreement with a recently appointed officer, whereby it authorized the issuance of 1,000,000 shares of common stock to such officer (see 8-K issued May 21, 2021)

 

On May 7, 2021, the Company deemed in the best interest to settle any and all of the Company's prior convertible debt with Crown Bridge Partners and allow for the cashless exercise to purchase 1,921,875 shares of PCT LTD's common stock (par value $0.001/share) at the rate of $0.032/share, thereby reducing PCT LTD's prior debt to Crown Bridge Partners to $0. In addition, Crown Bridge Partners shall release 60,072,853 shares to the agreed upon payment terms of $36,994 cash.

 

On June 2, 2021, the Company paid $25,000 to a non-related party toward a $150,000 Convertible Note dated April 9, 2020.

 

One June 2, 2021, the Company entered into a subscription and purchase agreement with a non-related party consisting of 3,750,000 restricted shares of common stock (aggregate) at a price per share of $0.02 for $75,000 cash.

 

One June 30 2021, the Company entered into a subscription and purchase agreement with a non-related party consisting of 5,000,000 restricted shares of common stock (aggregate) at a price per share of $0.02 for $100,000 cash.

 

On September 1, 2021, the Company issued 8,000,000 common shares and paid $21,000 to settle the remaining outstanding principal on a convertible note payable with Auctus Fund, LLC, of $88,795 and accrued interest of $26,153.

 

On September 10, 2021, the Company issued 2,000,000 common shares pursuant to a general release agreement dated July 23, 2021 with a former employee of the Company.

 

All of the above-described issuances were exempt from registration pursuant to Section 4(a)(2) and/or Regulation D of the Securities Act as transactions not involving a public offering. With respect to each transaction listed above, no general solicitation was made by either the Company or any person acting on its behalf. All such securities issued pursuant to such exemptions are restricted securities as defined in Rule 144(a)(3) promulgated under the Securities Act, appropriate legends have been placed on the documents evidencing the securities and may not be offered or sold absent registration or pursuant to an exemption therefrom.

 

Issuer Purchases of Equity Securities

 

We did not repurchase any of our equity securities during the quarter ended September 30, 2021.

 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

We have entered into a number of promissory notes, some of which are in default as of September 30, 2021, or went into default before the filing of this Quarterly Report (See Note 6 to the financial statements).

 

A significant portion of our current debt is in default, which may subject us to litigation by the debt holders.

 

As of September 30, 2021, we had cash and cash equivalents of $239,327 and had a significant amount of short-term debt in default. Management's plan is to raise additional funds in the form of debt or equity in order to continue to fund losses until such time as revenues are able to sustain the Company. To date, the main source of funding has been through the issuance of convertible notes with provisions that allow the holder to convert the debt and accrued and unpaid interest at substantial discounts to the trading price of our common stock. The effect of the conversions in the year ended December 31, 2020 and the period ended September 30, 2021 for the convertible notes has been to substantially dilute existing holders of common stock of our Company. However, there is no assurance that management will be successful in being able to continue to obtain additional funding or defend potential litigation by note holders.

 

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

 

ITEM 5. OTHER INFORMATION

 

Not applicable.

 

 

  32  

 

ITEM 6. EXHIBITS

 

Exhibit No. Description
3(i) Amended and Restated Articles of Incorporation, as currently in effect (Incorporated by reference to Exhibit 3.1 of Form 8-K, filed April 13, 2018)
3.1 Amended Articles of Incorporation increasing authorized shares (Incorporated by reference to Exhibit 3.1 of Form 8-K, filed on October 25, 2019)
3(ii) Amended and Restated Bylaws, as currently in effect (Incorporated by reference to Exhibit 3.2 of Form 8-K, filed April 13, 2018)
4.1 Certificate of Designation of Series A Convertible Preferred Stock (Incorporated by reference to Exhibit 4.1 of Form 10-Q, filed on September 16, 2019)
4.2 Certificate of Designation of Series B - Super Voting Convertible Preferred Stock (Incorporated by reference to Exhibit 4.2 of Form 10-Q, filed on September 16, 2019)
4.3 Certificate of Designation of Series C Convertible Preferred Stock (Incorporated by reference to Exhibit 3.1 of Form 8-K, filed on October 25, 2019)
4.4 Power Up Note dated June 5, 2018 (Incorporated by reference to Exhibit 4.1 of Form 10-Q, filed August 20, 2018)
4.5 Second Power Up Note dated July 25, 2018 (Incorporated by reference to Exhibit 4.2 of Form 10-Q, filed August 20, 2018)
4.6 Third Power Up Note dated August 27, 2018 (Incorporated by reference to Exhibit 4.3 of Form 10-Q, filed November 21, 2019)
4.7 Fourth Power Up Note dated December 5, 2018 (Incorporated by reference to Exhibit 4.6 of Form 10-Q, filed on September 16, 2019)
4.8 Fifth Power Up Note dated January 15, 2019 (Incorporated by reference to Exhibit 4.7 of Form 10-Q, filed on September 16, 2019)
4.9 Sixth Power Up Note dated February 22, 2019 (Incorporated by reference to Exhibit 4.8 of Form 10-Q, filed on September 16, 2019)
4.10 GS Capital Note dated January 16, 2019 (Incorporated by reference to Exhibit 4.9 of Form 10-Q, filed on September 16, 2019)
4.11 JSJ Note dated January 22, 2019 (Incorporated by reference to Exhibit 4.10 of Form 10-Q, filed on September 16, 2019)
4.12 EMA Note dated January 22, 2019 (Incorporated by reference to Exhibit 4.11 of Form 10-Q, filed on September 16, 2019)
4.13 Adar Note dated February 20, 2019 (Incorporated by reference to Exhibit 4.12 of Form 10-Q, filed on September 16, 2019)
4.14 Peak One Note dated February 21, 2019 (Incorporated by reference to Exhibit 4.13 of Form 10-Q, filed on September 16, 2019)
4.15 Auctus Note dated March 13, 2019 (Incorporated by reference to Exhibit 4.14 of Form 10-Q, filed on September 16, 2019)
4.16 Peak One Opportunity Fund Note dated September 16, 2019 (Incorporated by reference to Exhibit 4.16 of Form 10-Q, filed on August 14, 2020)
4.17 Power-Up #8 Note dated October 8, 2019 (Incorporated by reference to Exhibit 4.17 of Form 10-Q, filed on August 14, 2020)
4.18 Power-Up #9 Note dated October 31, 2019 (Incorporated by reference to Exhibit 4.18 of Form 10-Q, filed on August 14, 2020)
4.19 Power-Up #10 Note dated March 2, 2020 (Incorporated by reference to Exhibit 4.19 of Form 10-Q, filed on August 14, 2020)
4.20 TFK Investments Note dated April 10, 2020 (Incorporated by reference to Exhibit 4.20 of Form 10-Q, filed on August 14, 2020)
4.21 Power-Up #11 Note dated April 16, 2020 (Incorporated by reference to Exhibit 4.21 of Form 10-Q, filed on August 14, 2020)
4.22 Herschbach 2005 Trust Consolidated Note dated May 5, 2020 (Incorporated by reference to Exhibit 4.22 of Form 10-Q, filed on August 14, 2020)
4.23 Power-Up #12 Note dated May 12, 2020 (Incorporated by reference to Exhibit 4.23 of Form 10-Q, filed on August 14, 2020)
4.24 Digital Ally Note dated July 7, 2020 (Incorporated by reference to Exhibit 4.24 of Form 10-Q, filed on August 14, 2020)
4.25 Reserve Capital Management Note dated July 15, 2020 (Incorporated by reference to Exhibit 4.25 of Form 10-Q, filed on August 14, 2020)
10.1 Agreement with Annihilyzer, Inc. dated November 29, 2016 (Incorporated by reference to Exhibit 10.1 of Form 8-K, filed April 20, 2017)
10.2 Amendment to Agreement with Annihilyzer, Inc. dated April 6, 2017 (Incorporated by reference to Exhibit 10.2 of Form 8-K, filed April 20, 2017)
10.3 Read Consolidated Promissory Note dated September 27, 2017 (Incorporated by reference to Exhibit 10.1 of Form 8-K, filed October 4, 2017)
10.4† Paris Employment Agreement (Incorporated by reference to Exhibit 10.5 of Form 10-Q, filed November 14, 2017)
10.5 Strategic Planning Services Agreement dated March 15, 2018
10.6 Power Up Agreement dated June 5, 2018 (Included in Exhibit 4.1, which is incorporated by reference to Exhibit 4.1 of Form 10-Q, filed August 20, 2018)
10.7 Second Power Up Agreement dated July 25, 2018 (Included in Exhibit 4.2, which is incorporated by reference to Exhibit 4.2 of Form 10-Q, filed August 20, 2018
10.8 Third Power Up Agreement dated August 27, 2018 (Included in Exhibit 4.3, which is incorporated by reference to Exhibit 4.3 of Form 10-Q, filed November 21, 2019)
10.9 Fourth Power Up Agreement dated December 15, 2018 (Incorporated by reference to Exhibit 10.9 of Form 10-Q, filed on September 16, 2019)
10.10 Fifth Power Up Agreement dated January 15, 2019 (Incorporated by reference to Exhibit 10.10 of Form 10-Q, filed on September 16, 2019)
10.11 Sixth Power Up Agreement dated February 22, 2019 (Incorporated by reference to Exhibit 10.11 of Form 10-Q, filed on September 16, 2019)
10.12 GS Capital Agreement dated January 16, 2019 (Incorporated by reference to Exhibit 10.12 of Form 10-Q, filed on September 16, 2019)
10.13 JSJ Agreement dated January 22, 2019 (Incorporated by reference to Exhibit 10.13 of Form 10-Q, filed on September 16, 2019)
10.14 EMA Agreement dated January 22, 2019 (Incorporated by reference to Exhibit 10.14 of Form 10-Q, filed on September 16, 2019)
10.15 Adar Agreement dated February 20, 2019 (Incorporated by reference to Exhibit 10.15 of Form 10-Q, filed on September 16, 2019)
10.16 Peak One Agreement dated February 21, 2019 (Incorporated by reference to Exhibit 10.16 of Form 10-Q, filed on September 16, 2019)
10.17 Auctus Agreement dated March 13, 2019 (Incorporated by reference to Exhibit 10.17 of Form 10-Q, filed on September 16, 2019)
10.18† Read Employment Agreement (Incorporated by reference to Exhibit 10.18 of Form 10-Q, filed on September 16, 2019)
10.19† Read Addendum to Employment Agreement (Incorporated by reference to Exhibit 10.19 of Form 10-Q, filed on September 16, 2019)
10.20† Grieco 2019 Employment Agreement (Incorporated by reference to Exhibit 10.20 of Form 10-Q, filed on September 16, 2019)
10.21† Grieco 2020 Employment Agreement Incorporated by reference to Exhibit 10.21 of Form 10-Q, filed on April 13, 2020)
10.22 Peak One Opportunity Fund Agreement dated September 16, 2019 (Incorporated by reference to Exhibit 10.22 of Form 10-Q, filed on August 14, 2020)
10.23 Power-Up #8 Agreement dated October 8, 2019 (Incorporated by reference to Exhibit 10.23 of Form 10-Q, filed on August 14, 2020)
10.24 Power-Up #9 Agreement dated October 31, 2019 (Incorporated by reference to Exhibit 10.24 of Form 10-Q, filed on August 14, 2020)
10.25 Power-Up #10 Agreement dated March 2, 2020 (Incorporated by reference to Exhibit 10.25 of Form 10-Q, filed on August 14, 2020)
10.26 TFK Investments Agreement dated April 10, 2020 (Incorporated by reference to Exhibit 10.26 of Form 10-Q, filed on August 14, 2020)
10.27 Power-Up #11 Agreement dated April 16, 2020 (Incorporated by reference to Exhibit 10.27 of Form 10-Q, filed on August 14, 2020)
10.28 Herschbach 2005 Trust Agreement dated May 12, 2020 (Incorporated by reference to Exhibit 10.28 of Form 10-Q, filed on August 14, 2020)
31.1 Principal Executive Officer Certification
31.2 Principal Financial Officer Certification
32.1 Section 1350 Certification
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Label Linkbase Document
101.PRE XBRL Taxonomy Presentation Linkbase Document

 

† Indicates management contract or compensatory plan or arrangement. 

 

 

  33  

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    PCT LTD
     
     
Date: November 15, 2021 By: /s/ Gary Grieco
    Gary Grieco, Principal Executive Officer
    Chief Executive Officer and Chairman

 

 

33

1 Year PCT (CE) Chart

1 Year PCT (CE) Chart

1 Month PCT (CE) Chart

1 Month PCT (CE) Chart